In the latest close session, Zoetis (ZTS - Free Report) was down 1.18% at $81.03. The stock trailed the S&P 500, which registered a daily loss of 0.52%. On the other hand, the Dow registered a loss of 1.24%, and the technology-centric Nasdaq decreased by 0.21%.
Shares of the animal health company have appreciated by 16.69% over the course of the past month, outperforming the Medical sector's gain of 3.23%, and the S&P 500's loss of 1.21%.
The investment community will be closely monitoring the performance of Zoetis in its forthcoming earnings report. The company is scheduled to release its earnings on November 5, 2026. The company's upcoming EPS is projected at $1.51, signifying a 11.18% drop compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.3 billion, indicating a 4.11% decrease compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.14 per share and revenue of $9.24 billion, which would represent changes of -4.21% and -2.39%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Zoetis. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.96% lower within the past month. Zoetis is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, Zoetis currently has a Forward P/E ratio of 13.35. This indicates a discount in contrast to its industry's Forward P/E of 16.81.
It is also worth noting that ZTS currently has a PEG ratio of 1.21. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - Drugs industry had an average PEG ratio of 1.9.
The Medical - Drugs industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 92, positioning it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ZTS in the coming trading sessions, be sure to utilize Zacks.com.
Zoetis Inc. (ZTS - Free Report) and ImmuCell Corporation (ICCC - Free Report) operate in the animal health industry but present distinctly different investment opportunities. While Zoetis benefits from an extensive portfolio of veterinary medicines, vaccines and diagnostics across companion animals and livestock, ImmuCell concentrates on preventive health products for newborn calves.
Let us examine how ZTS and ICCC compare across the factors that could influence their investment prospects.
The Case for ZTSDiversified Portfolio Offers Resilience: Zoetis benefits from a broad animal health portfolio spanning companion animal therapeutics, livestock products and diagnostics. In the second quarter of 2026, livestock revenues grew 11% year over year on an organic operational basis, supported by strong cattle and poultry demand, while companion animal diagnostics advanced 12%. International revenues increased 6%, partially offsetting a 7% decline in U.S. revenues.
This diversification helps reduce the dependence on individual products and markets. However, consolidated organic operational revenues declined 1%, indicating that strength in livestock and diagnostics has not fully compensated for weaker companion animal demand.
Innovation Supports Long-Term Opportunities: Zoetis continues expanding its product portfolio through new therapies and diagnostic technologies. The launches of Lenivia and Portela in Canada and the European Union during 2026 broadened its osteoarthritis treatment offerings for dogs and cats.
International osteoarthritis pain monoclonal antibody revenues increased 7% in the second quarter, supported by these launches. The company also expects potential U.S. approval of long-acting Cytopoint during 2026 and commercial validation of its Vetscan OmniMax chemistry platform by year-end. These developments could support growth, although successful commercialization and customer adoption remain essential.
Companion Animal Weakness Remains Concerning: Zoetis continues to face fewer veterinary clinic visits, affordability pressures and aggressive promotional competition. Its key dermatology franchise revenues declined 16% organically in the second quarter of 2026, while its U.S. in-clinic dermatology market share fell five percentage points sequentially to approximately 86%.
The company reduced its 2026 revenue outlook to $9.12-$9.32 billion, implying an organic operational decline of 1-3%. Adjusted earnings per share are projected at $6.15-$6.25. With market conditions showing little stabilization through July, continued competitive pressure could delay recovery.
The Case for ICCCStrong Product Demand Drives Growth: ImmuCell reported first-half 2026 product sales of $17.5 million, increasing 20.9% from $14.5 million a year earlier. Its flagship Tri-Shield product recorded 25.1% growth, while domestic sales increased 32.5%. Distributor-level product volume growth accelerated from 21% in the first quarter to 28% in the second quarter. These trends reflect improved product availability, increased commercial activity and stronger customer demand.
The company's focus on calf scours prevention provides a defined growth opportunity, although its dependence on a relatively narrow product portfolio increases exposure to changes in demand and manufacturing performance.
Market Share Gains Strengthen Competitive Position: ImmuCell's First Defense portfolio continues to gain traction among U.S. dairy and beef producers. Its share of calves receiving biological scours prevention increased from approximately 15% in December 2025 to 19% by June 2026. Its share of producer spending also rose from around 29% to 38% over the same period.
Higher calf values have strengthened the economic incentive for disease prevention, with management indicating that the value of a day-old calf increased from approximately $400 to $1,700 since 2024. These developments support opportunities for additional market penetration, particularly as more than half of calves remain untreated with biological scours preventatives.
Capacity Expansion Creates Growth Potential: ImmuCell is undertaking an approximately $8-million manufacturing expansion to address historical production constraints and support demand for First Defense. The initial $3.5-million freeze-drying investment is expected to be completed in the first half of 2027, followed by a $4.5-million colostrum processing expansion targeted for the second half.
The company expects these investments to more than triple production capacity and reduce processing times from two to three months to less than one month. Successful execution could improve product availability and manufacturing economics, although expansion costs, equipment installation and process optimization introduce operational risks.
Manufacturing Costs Pressure Margins: Despite healthy sales growth, ImmuCell's second-quarter 2026 gross margin declined to 33.9% from 43.7% a year earlier. Lower manufacturing volumes, material-related scrap and the transfer of former Re-Tain development costs into production expenses contributed to the decline. Quarterly output averaged approximately 350,000 units per month compared with more than 450,000 units per month in the first quarter.
The company also faces growing competition for high-quality colostrum, which indicates half of product costs. These pressures could constrain profitability until manufacturing efficiencies and expansion benefits materialize.
ZTS or ICCC?Zoetis appears better positioned for investors prioritizing business diversification and established profitability. Its livestock, diagnostics and international businesses provide important offsets to U.S. companion animal weakness. Nevertheless, its lowered 2026 guidance and intensifying competitive pressures limit near-term operating momentum.
ImmuCell offers a stronger recent growth profile, supported by rising First Defense adoption, increasing market share and planned manufacturing improvements. However, its narrower business focus, gross-margin volatility and considerable expansion requirements introduce greater execution risks.
Overall, ZTS has the edge in financial resilience and business stability, while ICCC stands out for recent operating growth and potential capacity-driven expansion.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.
Banque Pictet and Cie SA reduced its holdings in shares of Zoetis Inc. (NYSE: ZTS) by 0.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,785,312 shares of the company's stock after selling 8,293 shares during the quarter.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of.
In this monthly series, I rank a selection of dividend growth stocks and present the top 10 stocks for consideration. This month's screen targets dividend growth stocks with Dividend Safety scores ≥8.0, forward yields ≥2.5%, and prices at or below fair value. An equally weighted portfolio of the top 10 stocks yields 2.8% but would have underperformed SPY over the past 5 years.
Though the S&P 500 remains near an all-time high, many steady-Eddie dividend stocks have not gone along for the ride. In fact, many of these top-tier dividend growth stocks have sold off sharply as the market shifted its focus to high-flying AI, semiconductor, and space stocks.
This market rotation leaves me eager to continue buying my favorite dividend payers at a discounted price, and I have identified two that look like once-in-a-decade opportunities right now. Down between 34% and 52%, here's the case for each stock and why I'll be buying each soon.
Image source: Getty Images.
1. Zoetis: Down 52% from its 52-week high Hand-up accountability: I have been wrong about leading animal and pet care behemoth Zoetis (ZTS +2.37%) over the last few years. The next chapter of the company's growth story (next-gen osteoarthritis medicines for dogs and cats) has stalled for now. This disappointment -- paired with continued declines in U.S. veterinary visits -- has weighed heavily upon the one premium-valued blue chip dividend stock.
Briefly trading at 70 times free cash flow (FCF) during its peak in 2023, Zoetis now trades at only 13 times FCF.
ZTS Price to Free Cash Flow data by YCharts
While there is no sugarcoating the company's recent results, where organic sales dipped 1% and earnings per share only rose 4% last quarter, this once-in-a-decade valuation implies that Zoetis will never grow again -- and I think that's a bit too negative.
The global animal healthcare market is still expected to grow by 5% annually through 2035, and Zoetis remains a leader in the space despite its recent slowdown. Outside of 2020 -- and likely 2026 -- Zoetis has grown sales faster than the broader animal healthcare industry every year since 2013, so this 5% growth could prove conservative.
This notion could prove especially true, since management expects to have 12 blockbusters (treatments with $100 million in annual sales) in its pipeline through 2030. Zoetis is home to 75 years of R&D experience in this niche, so I'm more than happy to receive a growing, well-funded dividend that currently yields 3% while I wait for newer treatments to be approved and to scale.
Premium Feature
Moneyball Superscore
69/100
Today's Change
(
2.37
%) $
1.73
Current Price
$
74.81
Lastly, I'm not the only one who thinks Zoetis stock is cheap. After lowering the company's share count by 1.8% annually over the last decade, management has swooped in and retired 8% of Zoetis' outstanding shares in the past year alone, hopefully capitalizing on the stock's deeply discounted price should it eventually rebound, as I expect over the long term.
2. Badger Meter: Down 34% from its 52-week high I've slowly built a starter position in smart water and advanced metering infrastructure (AMI) provider Badger Meter (BMI +2.91%) over the last couple of years, but the stock's recent dip has me ready to make it a full position. The serial acquirer's sales growth turned negative in its two most recent quarters after growing by double digits in 15 of the 17 previous quarters, and Badger Meter's stock was roughly halved over 18 months.
This sell-off leaves it trading near a decade-long low of 29 times earnings.
BMI PE Ratio data by YCharts
Better yet for investors, Badger Meter typically generates robust free cash flow (FCF), leaving it trading at an even more alluring 24 times FCF. Simply put, the company's valuation finally makes sense after trading at an average of nearly 50 times earnings over the last decade.
Certainly, declining sales for two straight quarters are eye-catching, but I think it should prove temporary. After growing sales by 24% in 2024 and 11% in 2025, this year's slowdown isn't catastrophic, given that the prior two years' growth was pulled forward more than usual. Furthermore, management explained that the sales figures are lumpy right now because four major projects just ended, while nine new ones are just now getting launched, causing the current cyclicality.
However, over the long haul, Badger Meter continues to shift more of its operations to SaaS sales as it helps water utilities modernize their outdated infrastructure. With 60% of U.S. water meter connections still using outdated meter-reading technologies, the company has immense room for continued growth as it replaces aging water equipment.
Premium Feature
Moneyball Superscore
75/100
Today's Change
(
2.91
%) $
3.72
Current Price
$
131.38
Whether it's simple water utility updates, adhering to water quality mandates, managing groundwater, addressing water overuse (a hot debate with data centers right now), monitoring droughts, or providing 24/7 communications to prevent longer-lasting water leaks, Badger Meter will likely only build upon its leadership position over the next decade.
Best yet, Badger Meter has grown its dividend payments by 15% annually over the past decade and will pay a 1.3% yield as investors wait for a turnaround in sales growth.
In the latest close session, Zoetis (ZTS - Free Report) was up +2.37% at $74.81. This change outpaced the S&P 500's 0.6% gain on the day. Elsewhere, the Dow gained 0.83%, while the tech-heavy Nasdaq added 0.64%.
Shares of the animal health company witnessed a gain of 0.3% over the previous month, beating the performance of the Medical sector with its loss of 1.97%, and underperforming the S&P 500's gain of 1.34%.
Market participants will be closely following the financial results of Zoetis in its upcoming release. The company plans to announce its earnings on November 5, 2026. The company is forecasted to report an EPS of $1.52, showcasing a 10.59% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.31 billion, indicating a 3.66% decrease compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $6.2 per share and a revenue of $9.24 billion, demonstrating changes of -3.28% and -2.45%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for Zoetis. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Right now, Zoetis possesses a Zacks Rank of #4 (Sell).
Digging into valuation, Zoetis currently has a Forward P/E ratio of 11.78. This expresses a discount compared to the average Forward P/E of 16.14 of its industry.
We can also see that ZTS currently has a PEG ratio of 1.7. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Drugs industry was having an average PEG ratio of 1.69.
The Medical - Drugs industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 190, placing it within the bottom 23% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Friday, October 30, 2026.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness supporting veterinarians, livestock producers and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows that not all heartworm preventives perform equally against these resistant isolates. Macrocyclic lactone (ML) resistance means some heartworm isolates are less sensitive to the drug class used in today's heartworm disease preventives. As ML resistance continues to challenge heartworm prevention, veterinarians need data th.
Rockland Trust Co. boosted its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 19.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 244,065 shares of the company’s stock after buying an additional 40,294 shares during the quarter. Rockland Trust Co. owned approximately 0.06% of Zoetis worth $17,043,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of ZTS. Louisiana State Employees Retirement System bought a new stake in shares of Zoetis during the 1st quarter worth $2,542,000. Wealthfront Advisers LLC boosted its holdings in Zoetis by 80.2% in the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after buying an additional 33,873 shares during the period. Deutsche Bank AG boosted its holdings in shares of Zoetis by 19.1% in the fourth quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after acquiring an additional 891,921 shares during the period. Pacer Advisors Inc. boosted its position in shares of Zoetis by 16.7% in the first quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock valued at $19,572,000 after acquiring an additional 23,687 shares during the period. Finally, Diamond Hill Capital Management LLC Investment Advisor lifted its stake in Zoetis by 21.5% in the 2nd quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock worth $255,637,000 after purchasing an additional 629,974 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Analyst Ratings Changes Several research analysts recently weighed in on the stock. HSBC decreased their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. BNP Paribas Exane decreased their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Barclays lowered their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Weiss Ratings reissued a “sell (d)” rating on shares of Zoetis in a research note on Wednesday, September 9th. Finally, TD Cowen cut their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $101.08.
View Our Latest Stock Analysis on Zoetis Zoetis Stock Up 1.2% Zoetis stock traded up $0.82 during mid-day trading on Monday, hitting $70.51. The company had a trading volume of 1,318,579 shares, compared to its average volume of 5,582,245. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The stock’s 50 day moving average price is $74.39 and its two-hundred day moving average price is $86.22. Zoetis Inc. has a 12 month low of $68.77 and a 12 month high of $148.30. The company has a market capitalization of $29.14 billion, a PE ratio of 11.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.74.
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue was down .2% on a year-over-year basis. During the same period last year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.
About Zoetis (Free Report)
Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.
The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.
Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.
Recommended Stories Five stocks we like better than Zoetis A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks Insiders Are Selling These 3 Stocks, Should You?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
Zoetis (ZTS - Free Report) ended the recent trading session at $69.10, demonstrating a -1.05% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.2%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.04%.
Shares of the animal health company witnessed a loss of 8.32% over the previous month, trailing the performance of the Medical sector with its loss of 1.75%, and the S&P 500's loss of 0.35%.
Analysts and investors alike will be keeping a close eye on the performance of Zoetis in its upcoming earnings disclosure. The company's earnings report is set to go public on November 5, 2026. The company is forecasted to report an EPS of $1.52, showcasing a 10.59% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.31 billion, down 3.66% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.2 per share and revenue of $9.24 billion, which would represent changes of -3.28% and -2.45%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Zoetis. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Zoetis boasts a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Zoetis is currently being traded at a Forward P/E ratio of 11.26. This signifies a discount in comparison to the average Forward P/E of 16.38 for its industry.
We can additionally observe that ZTS currently boasts a PEG ratio of 1.63. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical - Drugs industry was having an average PEG ratio of 1.73.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 176, which puts it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of ZTS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
In the latest trading session, Zoetis (ZTS - Free Report) closed at $70.27, marking a -1.87% move from the previous day. This move lagged the S&P 500's daily loss of 0.03%. Elsewhere, the Dow lost 0.31%, while the tech-heavy Nasdaq added 0.01%.
Coming into today, shares of the animal health company had lost 7.62% in the past month. In that same time, the Medical sector lost 4.15%, while the S&P 500 gained 0.53%.
The investment community will be paying close attention to the earnings performance of Zoetis in its upcoming release. It is anticipated that the company will report an EPS of $1.52, marking a 10.59% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $2.31 billion, down 3.66% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.2 per share and revenue of $9.24 billion, which would represent changes of -3.28% and -2.45%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Zoetis. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.09% higher within the past month. As of now, Zoetis holds a Zacks Rank of #5 (Strong Sell).
In terms of valuation, Zoetis is presently being traded at a Forward P/E ratio of 11.54. Its industry sports an average Forward P/E of 16.15, so one might conclude that Zoetis is trading at a discount comparatively.
It's also important to note that ZTS currently trades at a PEG ratio of 1.67. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Drugs stocks are, on average, holding a PEG ratio of 1.75 based on yesterday's closing prices.
The Medical - Drugs industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 157, positioning it in the bottom 37% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://in.
In the latest close session, Zoetis (ZTS - Free Report) was down 2.22% at $71.40. This change lagged the S&P 500's 0.17% gain on the day. Elsewhere, the Dow saw a downswing of 0.18%, while the tech-heavy Nasdaq appreciated by 0.4%.
The animal health company's shares have seen a decrease of 2.67% over the last month, not keeping up with the Medical sector's gain of 0.65% and the S&P 500's loss of 1.29%.
Investors will be eagerly watching for the performance of Zoetis in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.52, signifying a 10.59% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $2.31 billion, indicating a 3.66% decline compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of $6.2 per share and a revenue of $9.24 billion, demonstrating changes of -3.28% and -2.45%, respectively, from the preceding year.
Investors should also pay attention to any latest changes in analyst estimates for Zoetis. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.09% upward. Zoetis is holding a Zacks Rank of #5 (Strong Sell) right now.
Digging into valuation, Zoetis currently has a Forward P/E ratio of 11.77. This signifies a discount in comparison to the average Forward P/E of 16.09 for its industry.
We can additionally observe that ZTS currently boasts a PEG ratio of 1.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Medical - Drugs industry had an average PEG ratio of 1.78.
The Medical - Drugs industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 159, placing it within the bottom 36% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Which Pet Stock Should Get Your Tail Wagging in 2024?Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides.
Speaking at a Morgan Stanley conference, CEO Kristin Peck said the company’s revised operational revenue outlook of negative 3% to negative 1% reflects both industry conditions and company-specific competitive dynamics. Zoetis had previously forecast operational revenue growth of 2% to 5%.
Get Zoetis alerts:
MarketBeat Week in Review – 07/31 - 08/04“For the first time, we saw a declining pet care market,” Peck said, pointing to lower veterinary visits and affordability challenges for pet owners. She said parasiticides declined 6.7% industrywide, while demand has been stronger in diagnostic testing and products associated with specialty, urgent and critical care.
Targeted Promotions and Competitive Pressure Peck characterized the company’s current pricing pressure as cyclical rather than structural. Zoetis has not broadly reduced list prices for its key dermatology and parasiticide products, she said. Instead, the company has used targeted, time-limited promotions and discounts intended to win business from customers using competing products.
Rising Dividend Make Zoetis a Doggone Winner“This isn’t everybody, 10% discount for anyone who wants to buy,” Peck said. “This is, you’re buying my competitor’s product today, we want to be your parasiticide of choice.”
The company began many of those targeted programs in the second quarter and made them more aggressive in the third quarter after initial promotions did not deliver the desired results. Peck said Zoetis will assess the programs each quarter and adjust their scope and intensity as needed.
She said the company is pleased with the early performance of the actions, while noting that competition can prompt responses from rivals. Zoetis is seeking to protect market share, particularly in categories where it historically held dominant positions, while also using its broad product portfolio and pipeline to support relationships with veterinarians and corporate veterinary customers.
Jay Saccaro, Zoetis’ recently appointed CFO and COO, said he was attracted to the company by its leadership position, commercial capabilities and innovation pipeline. After several weeks in the role, he said his initial observations have been “confirmatory,” including the strength of the company’s products and the engagement of its employees.
Saccaro said the company’s assumptions about market conditions are tracking as expected and that management remains confident in guidance. Zoetis plans to update investors in November.
Parasiticides, Dermatology and Product Pipeline In parasiticides, Peck said Zoetis remains the U.S. market-share leader, with nearly twice the share of the next competitor. The company’s share declined about 1% during the prior quarter, which she described as relatively stable amid competitive activity.
Zoetis continues to see an opportunity to expand the parasiticide market by converting customers from single agents, collars and topical products to triple-combination products. International markets also remain a growth opportunity, Peck said, citing the recent launch of Simparica Trio in Brazil.
In dermatology, Zoetis faces a third entrant competing against Apoquel. Peck said the company finished the quarter with approximately 87% U.S. share for Apoquel, while acknowledging that its historically high share will decline as competitors enter. Zoetis expects an approval for long-acting Cytopoint Plus in the U.S. by year-end and continues to promote Apoquel Chewable, Apoquel and Cytopoint as a differentiated portfolio.
Peck said Apoquel’s first loss of exclusivity is expected in 2032, excluding the chewable formulation. She also highlighted an estimated 16 million untreated dogs in the U.S. with dermatological conditions as an opportunity to expand treatment.
Management expects the penetration of newly launched dermatology products to take roughly 18 months historically, though Peck said the pace could vary. Zoetis is watching both share movements and a potential recovery in the broader pet-care market to determine when promotional spending can normalize.
Renal Disease, Oncology and Livestock Growth Zoetis identified chronic kidney disease, oncology, cardiology, anxiety, diabetes and obesity as important pipeline opportunities. Peck said renal disease is the nearest-term and largest of those opportunities, describing an approximately $3 billion addressable market.
The company has a renal product targeted for approval at the end of next year that is intended to slow disease progression, along with planned diagnostics, biomarkers and additional therapies. Peck said roughly 20% of dogs and 40% of cats develop renal or chronic kidney disease.
Zoetis also has two oncology products in its pipeline, including one management believes could become a blockbuster product, defined by the company as one with potential annual sales of $1 billion. The company expects oncology therapies will need to be suitable for use by general veterinary practitioners, in addition to specialists.
Meanwhile, livestock has produced double-digit growth this year, according to Peck. She attributed the strength partly to higher protein consumption in developed markets associated with GLP-1 medicines. Growth has extended across species, with fish and poultry the fastest-growing globally and continued strength in U.S. beef and dairy cattle.
Zoetis has also reduced list prices for Cerenia and Convenia in response to generic competition, a structural pricing action distinct from its targeted promotions in dermatology and parasiticides. Peck said the company does not expect other large products to face generic competition before 2032.
About Zoetis (NYSE:ZTS)Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.
The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Zoetis Right Now?Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin compression due to promotions and rebates. Long-term growth is supported by structural pet humanization trends, international expansion, a robust R&D pipeline, and a growing diagnostics segment.
Zoetis Inc. (ZTS) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:50 PM EDT
Company Participants
James Saccaro - Executive VP, CFO & COO
Kristin Peck - CEO & Director
Conference Call Participants
Erin Wilson Wright - Morgan Stanley, Research Division
Presentation
Erin Wilson Wright
Morgan Stanley, Research Division
Good afternoon, everyone. My name is Erin Wright. I'm the lead health care services analyst at Morgan Stanley. We're happy to have Zoetis with us today. But first, for more important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.
And with that, thanks so much for joining us today. We have CEO, Kristin Peck; and CFO and COO or recently appointed CFO and COO, Jay Saccaro, with us as well today. There's a lot to get into a very pivotal time, I think, for Zoetis. So we'll go ahead and get started.
Question-and-Answer Session
Erin Wilson Wright
Morgan Stanley, Research Division
And Jay, I think you wanted to make some intro remarks, so I'll tee it up for you. And just after a long tenure at Baxter, then at GE Healthcare, why did you choose Zoetis? And now that you're kind of that month in, what are some of those initial observations since you've joined? And any sort of near-term goals you can share?
James Saccaro
Executive VP, CFO & COO
Great. First of all, thanks for the invitation to the conference. We appreciate it. Thanks to those who are joining us today. We appreciate your interest in our company. For me, I was really excited about a few things. I think there's a huge value creation opportunity at Zoetis and was really excited to get after that. I also really appreciated the great management team, great CEO. And I also felt like I could contribute in terms of helping the company move forward on the journey. But
Corient Private Wealth LP lowered its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 8.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 487,990 shares of the company’s stock after selling 47,682 shares during the period. Corient Private Wealth LP owned 0.12% of Zoetis worth $35,067,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of ZTS. California State Teachers Retirement System raised its holdings in Zoetis by 6,680.3% during the 2nd quarter. California State Teachers Retirement System now owns 47,745,365 shares of the company’s stock worth $3,430,982,000 after purchasing an additional 47,041,186 shares during the last quarter. BlackRock Inc. raised its stake in shares of Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after buying an additional 3,845,869 shares during the last quarter. J. Stern & Co. LLP raised its stake in shares of Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after buying an additional 23,877,416 shares during the last quarter. State Street Corp lifted its holdings in Zoetis by 0.8% in the fourth quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after buying an additional 149,382 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Zoetis by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after acquiring an additional 189,235 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.
Analyst Upgrades and Downgrades A number of analysts have recently commented on the company. BNP Paribas Exane lowered their price target on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 11th. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Zoetis in a report on Wednesday. Finally, UBS Group cut their price target on Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Zoetis presently has a consensus rating of “Hold” and a consensus target price of $101.08.
Read Our Latest Analysis on Zoetis Zoetis Stock Performance NYSE:ZTS opened at $73.05 on Monday. The firm has a market capitalization of $30.19 billion, a PE ratio of 12.03, a price-to-earnings-growth ratio of 1.70 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The stock’s 50-day simple moving average is $75.56 and its 200 day simple moving average is $91.73. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $150.05.
Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter last year, the business posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.
About Zoetis (Free Report)
Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.
The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.
Featured Stories Five stocks we like better than Zoetis Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound 3 Small-Cap Biotechs With Binary Catalysts on the Calendar Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
Zoetis (NYSE:ZTS – Get Free Report) and Urogen Pharma (NASDAQ:URGN – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.
Profitability This table compares Zoetis and Urogen Pharma’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Zoetis 27.49% 74.89% 18.59% Urogen Pharma -51.73% N/A -43.79% Valuation & Earnings This table compares Zoetis and Urogen Pharma”s revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zoetis $9.47 billion 3.20 $2.67 billion $6.07 12.09 Urogen Pharma $109.79 million 20.03 -$153.49 million ($1.98) -22.73 Zoetis has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings This is a summary of current ratings for Zoetis and Urogen Pharma, as reported by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zoetis 2 9 8 0 2.32 Urogen Pharma 1 1 7 1 2.80 Zoetis currently has a consensus price target of $101.08, indicating a potential upside of 37.72%. Urogen Pharma has a consensus price target of $50.38, indicating a potential upside of 11.94%. Given Zoetis’ higher possible upside, equities analysts plainly believe Zoetis is more favorable than Urogen Pharma.
Risk and Volatility Zoetis has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.
Insider & Institutional Ownership 92.8% of Zoetis shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 4.8% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary Zoetis beats Urogen Pharma on 10 of the 15 factors compared between the two stocks.
About Zoetis (Get Free Report)
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
About Urogen Pharma (Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
HB Wealth Management LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 190.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,820 shares of the company’s stock after acquiring an additional 25,433 shares during the quarter. HB Wealth Management LLC’s holdings in Zoetis were worth $2,790,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the stock. RFG Advisory LLC boosted its position in shares of Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after purchasing an additional 80 shares during the period. Financial Engines Advisors L.L.C. increased its position in Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after buying an additional 87 shares during the period. Physician Wealth Advisors Inc. lifted its stake in Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after buying an additional 91 shares during the last quarter. Smithfield Trust Co lifted its stake in Zoetis by 4.2% in the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after buying an additional 92 shares during the last quarter. Finally, Howland Capital Management LLC boosted its holdings in shares of Zoetis by 4.5% in the second quarter. Howland Capital Management LLC now owns 2,137 shares of the company’s stock valued at $333,000 after acquiring an additional 92 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.
Wall Street Analysts Forecast Growth A number of equities analysts have recently issued reports on ZTS shares. Piper Sandler lowered their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, August 10th. Barclays reduced their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Citigroup decreased their price target on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. William Blair reissued a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Finally, UBS Group dropped their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $101.08.
Check Out Our Latest Stock Report on Zoetis Zoetis Stock Performance Shares of ZTS opened at $73.56 on Wednesday. The stock has a market capitalization of $30.40 billion, a P/E ratio of 12.12, a P/E/G ratio of 1.77 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis Inc. has a 1 year low of $71.00 and a 1 year high of $152.12. The company’s fifty day moving average is $75.61 and its two-hundred day moving average is $92.87.
Zoetis (NYSE:ZTS – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue was down .2% on a year-over-year basis. During the same quarter last year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current year.
About Zoetis (Free Report)
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Stories Five stocks we like better than Zoetis Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET.
Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
Blackhill Capital Inc. cut its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 28.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,296 shares of the company’s stock after selling 27,603 shares during the quarter. Zoetis accounts for approximately 0.2% of Blackhill Capital Inc.’s holdings, making the stock its 20th biggest position. Blackhill Capital Inc.’s holdings in Zoetis were worth $4,908,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of ZTS. Prosperity Bancshares Inc acquired a new stake in Zoetis in the fourth quarter valued at about $25,000. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis during the 1st quarter worth approximately $28,000. Elyxium Wealth LLC purchased a new position in shares of Zoetis during the 4th quarter worth approximately $32,000. Root Financial Partners LLC raised its stake in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares in the last quarter. Finally, Wellington Grp LLC lifted its holdings in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after buying an additional 267 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.
Zoetis Stock Performance NYSE:ZTS opened at $77.45 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market capitalization of $32.00 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 1.75 and a beta of 0.74. The firm has a 50-day moving average price of $75.57 and a two-hundred day moving average price of $95.62. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $156.49.
Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year. Analyst Upgrades and Downgrades Several research firms have issued reports on ZTS. Citigroup cut their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. BNP Paribas Exane decreased their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. TD Cowen lowered their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Finally, Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $107.43.
Check Out Our Latest Stock Analysis on Zoetis
About Zoetis (Free Report)
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Recommended Stories Five stocks we like better than Zoetis 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
Phibro Animal Health's Zoetis MFA acquisition has created a larger animal health platform with stronger earnings and broader manufacturing reach. Vaccines, nutritional specialties, and companion-animal expansion give PAHC newer growth verticals beyond the legacy MFA franchise. Management's optimization program and Chicago Heights consolidation could improve efficiency as the acquired portfolio moves beyond integration.
Dividend growth stocks can be attractive long-term buys, as the income they provide is likely to rise over time. But many stocks that have long streaks don't often raise their payouts at high rates, so while their streaks are getting longer, the increases don't often amount to much. Investors may be wondering what the point is at that stage, since it effectively becomes more about extending the streak rather than significantly growing dividend income.
The three dividend stocks on this list, however, have been generous with their dividend increases. They may not have exceptionally long track records of dividend growth, but over the past five years, they have more than doubled their payouts. The stocks I'm talking about are Tractor Supply Company (TSCO +2.68%), Zoetis (ZTS +2.64%), and Energy Transfer LP (ET +0.42%). They also have yields that are far higher than the S&P 500 average of just 1%.
Image source: Getty Images.
Tractor Supply CompanyTractor Supply Company sells essential products for farms, ranches, homes, and animals. The rural lifestyle retailer has thousands of stores throughout the country and has been around for over 85 years.
This year, however, the stock has struggled due to a poor outlook and weaker economic conditions, with discretionary spending down. The stock has fallen by more than 40% in just the past 12 months.
Today's Change
(
2.68
%) $
0.93
Current Price
$
35.65
As a long-term investment, however, there may be some intrigue here from investors. It trades at 18 times earnings and yields 2.8%. Its current quarterly dividend is 24 cents. It did a 5-for-1 stock split in 2024, so the 52-cent dividend it was paying in 2021 is the equivalent of 10.4 cents on a split-adjusted basis. Thus, its dividend has increased by around 131% since then.
Although the stock hasn't been doing that well of late, its payout ratio remains manageable at around 50%, suggesting there may still be room for more increases in the future. For investors willing to hang on and be patient, this may be a good, undervalued stock to buy right now.
ZoetisZoetis is an animal health company that makes a wide range of products for animals, including vaccines and medicines. Its business can generate a steady stream of income due to the necessities it offers.
However, like Tractor Supply, it's also been struggling of late due to economic challenges and questions about its future growth. Things haven't been great, but the company's sales are still up 1% over the first six months of the year, and its profits have declined by a modest 3%. The panic in the market may be a bit extreme.
Today's Change
(
2.64
%) $
1.95
Current Price
$
75.91
The sell-off in the stock has pushed its yield up to around 2.9%. Currently, it's paying investors 53 cents per share in dividends each quarter, up from 25 cents five years ago, which translates into an increase of 112%.
Its payout ratio is low at 34%, and at 12 times its trailing earnings, the stock's valuation is also low. For both contrarian and income-seeking investors, Zoetis is another stock that may prove to be an underrated buy in the long run.
Energy TransferUnlike the other stocks on this list, shares of Energy Transfer are up 24% over the past 12 months. The pipeline company has been benefiting from growing bullishness in the energy sector due to elevated oil prices. The company prides itself on "safely delivering America's energy" and being a key player in the sector.
During the first six months of the year, the company's revenue has grown by 54%, to $62.1 billion. Its business is benefiting from strong demand for natural gas liquids and increases in crude oil transportation.
Today's Change
(
0.42
%) $
0.09
Current Price
$
21.51
Even with its share price rising considerably over the past year, the stock still offers the highest yield on this list, paying around 6.4%. Its quarterly dividend is currently 34 cents, and that has increased by 123% from five years ago, when it was paying 15.25 cents per quarter.
The company's distributable cash flow in the most recent quarter rose by 32%, to $2.59 billion. That's a good sign that not only is the dividend in good shape, supported by strong financials, but that there may still be more room for it to rise higher.
For investors looking for a top energy stock to buy that also pays a high yield, Energy Transfer could make for an excellent option right now.
Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic traffic and heightened competition across key companion animal franchises. Despite aggressive competitor promotions, Zoetis protects industry-leading profitability (35%–37% EBIT margins) using targeted gross-to-net rebates rather than base list-price cuts. Trading at a historic low 12x P/E and a 7%+ FCF yield, Zoetis offers a strong margin of safety compared to its Base Case DCF fair value of $100.06.
Zoetis' Q2 earnings results were mixed, and the company cut its forward guidance. This has reduced the stock's margin of safety, but on balance, the risk/reward profile still favors the bulls. Zoetis has other segments performing well which partially offset the weakness in U.S. pet-related sales.
Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt.
The U.S. Food and Drug Administration on Thursday issued an emergency use authorization for Zoetis' flea and tick drug to treat New World screwworm (NWS) infestations in dogs and puppies.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax, commonly called New World screwworm (NWS), feed on living tissues, such as open wounds, of animals including livestock, wildlife and pets, and can inflict damage, pain and even death if not treated.
As New World screwworm continues to threaten the U.S.1 -- recently prompting several states to issue formal orders requiring treatment of domestic animals as part of cross-border animal movement from infested areas -- Zoetis is closely monitoring the situation and is committed to helping veterinarians and dog owners be prepared with solutions. Under an EUA, the FDA authorizes the use of a medication in an emergency to treat or prevent life-threatening diseases or conditions when certain criteria are met.
“At Zoetis, our highest priority is protecting the health and well-being of animals,” said Abhay Nayak, EVP and President, U.S. Commercial Operations at Zoetis. “The Emergency Use Authorization for Simparica Trio provides an important new tool in the fight against New World screwworm, a devastating parasite that can cause severe suffering in dogs. With this milestone, Simparica Trio helps simplify parasite protection for dogs with a single monthly chew—supporting both routine control and New World screwworm response needs.”
“We are deeply committed to supporting our customers with trusted, science-driven solutions—especially when rapid response and preparedness on key public health issues are critical. This Emergency Use Authorization for Simparica Trio builds on Zoetis’ expanding, multi-species set of solutions to help address New World screwworm across both companion animals and livestock,” Nayak continued. “Zoetis remains dedicated to advancing animal health and delivering the confidence our customers rely on, backed by Zoetis’ science, quality and manufacturing scale – so more animals can be protected, more consistently.”
Simparica Trio was the first product FDA-approved to provide all-in-one protection for dogs against heartworm disease, ticks and fleas, roundworms, hookworms, and prevents flea tapeworm infections by killing fleas in a single monthly chewable. It is FDA-approved to kill six species of ticks, including the Gulf Coast tick – providing comprehensive tick protection. While found all over the nation, the Gulf Coast tick is native to Southern U.S. states, including Texas.
Pet owners are encouraged to work closely with their veterinarian if they have any concerns about New World screwworm or other parasites. Reports of any suspicious wounds, maggots, or infestations should be made to a local veterinarian, state animal health official or the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS). USDA APHIS animal health contacts can be found at https://www.aphis.usda.gov/contact/animal-health.
As the leading animal health company, Zoetis has long supported a One Health approach to emerging and transboundary infectious diseases and has a strong track record of quickly developing innovative solutions to provide veterinarians and animal owners with the right mix of tools to prevent, control and treat disease in animals.
IMPORTANT SAFETY INFORMATION for Simparica Trio
Use with caution in dogs with a history of seizures. Simparica Trio contains sarolaner, a member of the isoxazoline class which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders. The safe use of Simparica Trio has not been evaluated in breeding, pregnant, or lactating dogs. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. See Full Prescribing Information at SimparicaTrioPI.com.
Treatment of New World screwworm in Other Species
In addition to the EUA for Simparica Trio, Zoetis offers Dectomax®-CA1 Injectable (doramectin injection), the only nonprescription conditionally approved parasite control product labeled for prevention and treatment of infestations caused by NWS larvae in cattle and for prevention of reinfestation for 21 days. This conditional approval applies to beef cattle, female dairy cattle less than 20 months of age, pregnant beef cows, newborn calves and bulls. Dectomax-CA1 is not for use in calves to be processed for veal. Dectomax-CA1 is not for use in female dairy cattle 20 months of age or older, except under the conditions of the Emergency Use Authorization (EUA) granted on May 19, 2026.
The U.S. Food and Drug Administration has issued an Emergency Use Authorization (EUA) for the use of the approved/conditionally approved products Dectomax/Dectomax-CA1 for the following indications:
The prevention and treatment of infestations caused by Cochliomyia hominivorax larvae (myiasis) in dairy cattle (lactating dairy cows, dry dairy cows, and replacement dairy heifers 20 months of age and older), except for calves to be processed for veal. The prevention of infestations caused by C. hominivorax larvae (myiasis) in swine, sheep except for lactating sheep, and deer. The prevention of infestations caused by C. hominivorax larvae (myiasis) in horses 1 year old and older. Early detection of New World screwworm and rapid response are crucial to protecting the health of companion animals and livestock.
Emergency Use Authorization for Simparica Trio for New World Screwworm
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Simparica Trio is not approved for this use.
Simparica Trio is approved for other uses in dogs and puppies.
For additional information on the EUA, please refer to the Simparica Trio EUA Fact Sheet.
Limitations of Authorized Use
Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.
Approved Indications for Simparica Trio
Simparica Trio is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and hookworm (L4, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala) infections. Simparica Trio kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, the prevention of Dipylidium caninum (tapeworm) infections as a direct result of killing Ctenocephalides felis vector fleas on the treated dog, and the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (Asian longhorned tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater. Simparica Trio is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
Please refer to the following fact sheets for additional information:
EUA - Simparica Trio Fact Sheet
EUA - Dairy Cattle, Swine, Sheep and Deer Fact Sheet
EUA - Horse Fact Sheet
For more information on NWS, visit FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies
Dectomax-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under NADA 141-616.
Important Information:
Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
Dectomax-CA1 Injectable (Cattle only), as authorized under the Conditional Approval for use against New World screwworm, has a 35-day pre-slaughter withdrawal period. Do not use in calves to be processed for veal. Do not use in female dairy cattle 20 months of age or older, except under the conditions of the Emergency Use Authorization. Use in dogs may result in fatalities.
Dectomax/Dectomax-CA1 Injectable Emergency Use Authorization, authorized for the duration of the emergency declaration, does not provide full or conditional approval, but the Center for Veterinary Medicine (CVM) at the Food and Drug Administration (FDA) has determined that Dectomax/Dectomax-CA1 may be effective and safe. Dectomax/Dectomax-CA1 Injectable, as authorized under the Emergency Use Authorization for use against New World screwworm, has a 35-day pre-slaughter withdrawal period for lactating dairy cattle, dry dairy cattle, replacement dairy heifers, sheep and deer, and a 24-day pre-slaughter withdrawal period for swine. Treated calves and calves born to treated cows should not be processed for veal. Withhold milk from dairy cattle for 468 hours (19.5 days) after treatment has ended. Not for use in lactating sheep. Not for use in horses less than 1 year of age.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements which reflect the current views of Zoetis with respect to regarding products, product approvals or licenses, products under development and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
ZTS-COR
ZTS-IR
ZTS-CA
1 APHIS. Current Status of New World Screwworm | Screwworm.gov Accessed 6/3/26.
Index Dow Jones -0,06 % na 53757,51 b. S&P 500 +0,25 % na 7747,61 b. Nasdaq Composite +0,64 % na 26614,82 b.
Nejsledovanější americké indexy v úvodu středečního obchodování posilují. Agentura Bloomberg poznamenala, že jádrová inflace v USA byla v červenci utlumená, což pravděpodobně zmírní tlak na americký Fed, aby zvyšoval úrokové sazby. Index spotřebitelských cen po očištění o často volatilní ceny potravin a energií vzrostl meziměsíčně o 0,2 %. V meziročním vyjádření se zvýšil o 2,5 %, což odpovídá nejpomalejšímu tempu od března 2021. Celkové spotřebitelské ceny vzrostly oproti předchozímu měsíci o 0,1 % a meziročně o 3,4 %.
Inflační data tak podle Bloombergu přinášejí částečnou úlevu obchodníkům na Wall Street, kteří se obávají přetrvávajících geopolitických rizik, zatímco index S&P 500 se drží poblíž historických maxim. Náladě pomáhá také růst technologických společností spojených s rozmachem umělé inteligence. V popředí dnešního růstu jsou akcie společností poskytujících AI cloudovou infrastrukturu CoreWeave (+19 %) a Nebius Group (+21 %). Daří se však také akciím dodavatele optických technologií pro datová centra Lumentum Holdings (+7 %) či výrobci serverů Super Micro Computer (+13 %) po reportu výsledků hospodaření. Své výsledky zveřejnil také čínský gigant Tencent (-4 %) či kanadský softwarový holding Constellation Software (-5 %).
Společnost Lumentum Holdings zaznamenala ve 4Q FY 2026 tržby ve výši 1,01 mld. USD, což bylo více než dvojnásobek loňské hodnoty 480,7 mil. USD a nad odhady trhu 990 mil. USD. Očištěný zisk na akcii činil 3,23 USD při konsensus 2,97 USD. Trh také pozitivně hodnotí výhled pro 1Q FY 2027, ve kterém společnost očekává tržby v rozmezí 1,23 až 1,28 mld. USD oproti odhadu 1,15 mld. USD a očištěný zisk na akcii v rozmezí 4,05 až 4,35 USD je též nad odhady 3,58 USD. Analytici z Vital Knowledge poznamenali, že čísla i výhled jsou velmi dobré, ale očekávání už byla poměrně vysoká.
Index S&P 500 +0,25 % na 7747,61 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Informační technologie +1,2 % Zbytná spotřeba -1 % Reality +0,5 % Základní materiály -0,7 % Utility +0,5 % Komunikační služby -0,7 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Super Micro Computer (SMCI) +13 % Builders FirstSource (BLDR) -4,5 % Ciena Corp (CIEN) +9,9 % Charter Communications (CHTR) -4,2 % Sandisk Corp (SNDK) +7,8 % ServiceNow (NOW) -3,8 % Seagate Technology Holdings (STX) +7,5 % Tapestry (TPR) -3,7 % Lumentum Holdings (LITE) +7,0 % Zoetis (ZTS) -3,7 % Zdroj: Bloomberg
Zoetis (NYSE:ZTS) reported second-quarter revenue of $2.5 billion, flat on a reported basis and down 1% organically, as pressure in U.S. companion-animal categories offset growth in livestock, diagnostics and international markets. Adjusted net income was $781 million, down 2% organically, while adjusted diluted earnings per share rose 4% to $1.87, benefiting from a lower share count following share repurchases.
Chief Executive Officer Kristin Peck said the quarter fell short of the company’s expectations amid declining veterinary clinic visits, more selective spending by pet owners and greater promotional activity from competitors. Zoetis lowered its full-year outlook, now expecting organic operational revenue to decline 3% to 1% and adjusted net income to decline 9% to 5%.
Companion-Animal Demand and Competition Weigh on Results Peck said veterinary clinic visits continued a multiyear decline, while price increases in pet care have outpaced broader consumer inflation. Pet owners have become more selective in their spending, with clinic revenue shifting toward urgent and emergency care and premium preventative and chronic-care products facing pressure, she said.
Global companion-animal revenue was $1.7 billion, down 6% in the quarter. U.S. companion-animal revenue declined 11% to $1 billion, while international companion-animal revenue increased 5% to $664 million.
Key dermatology revenue fell 16% to $395 million globally. In the U.S., dermatology revenue declined 18% to $251 million, as canine pruritic clinic visits fell by more than 2%, according to Peck. Chief Financial Officer Wetteny Joseph said the company’s U.S. dermatology franchise retained about 86% in-clinic share during the quarter, though share declined 5 percentage points sequentially and 10 points from a year earlier.
Zoetis has begun using targeted promotions, rebates and other “growth-to-net” investments to protect volume and share rather than lowering list prices, Peck said. Those actions can include clinic-specific promotions, cross-portfolio bundles and point-of-sale discounts for pet owners.
“We are not changing the list price of our products,” Peck said in response to analyst questions. “What we’re talking about is investments in what, in the industry, they’ll call growth to net.”
The Simparica franchise generated $442 million in revenue, flat globally. Simparica Trio revenue fell 1% to $350 million, while Simparica revenue rose 4% to $91 million. International franchise growth was offset by U.S. pressure from softer flea, tick and heartworm visits, as well as a more competitive and promotional marketplace.
U.S. Simparica franchise revenue declined 6% to $308 million. Joseph said Simparica Trio held approximately 21% in-clinic share in U.S. oral parasiticides, nearly double its nearest competitor, and its puppy share was about 28%.
OA Pain Products Show Mixed Performance Global osteoarthritis pain monoclonal-antibody revenue was $147 million, down 3%. Canine OA pain products Librela and Lenivia produced $105 million in revenue, down 8%, while feline OA pain products Solensia and Portela generated $42 million, up 12%.
U.S. canine OA pain revenue declined 24% to $34 million, reflecting a strong prior-year comparison, softer clinic traffic and affordability pressures on premium therapies. International OA pain revenue increased 7% to $96 million, supported by early launches of long-acting Lenivia and Portela in the European Union and Canada.
Peck said Zoetis expects U.S. approval of long-acting Cytopoint later in 2026. The company also said early experience with Lenivia and Portela has been encouraging and that it expects further market expansion in the coming year.
Diagnostics and Livestock Provide Offsets Companion-animal diagnostics revenue rose 12% to $118 million, driven by adoption of technologies including Vetscan Imagyst and Vetscan OptiCell. During the quarter, Zoetis completed its acquisition of VitalRADS, a veterinary teleradiology services platform, expanding its capabilities in veterinary imaging interpretation.
Peck said commercial validation of Vetscan OmniMax, a multimodal chemistry platform that the company views as a potential blockbuster opportunity, remains expected by year-end.
Livestock revenue increased 11% to $731 million, with U.S. livestock revenue rising 23% to $222 million. Growth was driven by cattle and poultry, improved product supply and elevated U.S. demand for Dectomax and other injectable parasiticides in connection with the New World screwworm outbreak.
Joseph said several factors behind the U.S. livestock performance were transitory, including supply timing and screwworm-related demand. Zoetis expects U.S. livestock growth to moderate to the mid-single-digit range in the second half, while citing mid- to high-single-digit growth as a sustainable range for the business’ broader fundamentals.
Guidance Reduced as July Trends Show No Stabilization Zoetis now expects 2026 revenue of $9.12 billion to $9.32 billion. It projected adjusted net income of $2.57 billion to $2.62 billion, adjusted diluted EPS of $6.15 to $6.25, and reported diluted EPS of $5.55 to $5.65.
Joseph said the revised forecast incorporates sales trends through July, which had “not yet indicated market stabilization.” The upper end assumes competitive and pricing pressures remain contained, while the lower end contemplates accelerated pressure, greater dermatology and parasiticide share losses, continued July-like weakness and slower livestock uptake.
The company also cited an additional foreign-exchange headwind of roughly $60 million to $65 million to revenue and about $30 million to profit compared with its prior outlook.
Zoetis repurchased more than $550 million of shares during the quarter. Joseph said the company is maintaining investment in R&D and selected commercial priorities while pursuing cost and productivity actions; adjusted SG&A declined 4% operationally in the quarter.
Separately, Peck said Abhay Nayak was promoted to executive vice president and president of U.S. Commercial Operations. Jay Saccaro will join Zoetis on Aug. 17 as executive vice president, chief financial officer and chief operating officer, a newly created role overseeing finance as well as global manufacturing and supply. Joseph will remain a special advisor on financial matters until early 2027 to support the transition.
About Zoetis (NYSE:ZTS) Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Zoetis Inc. (NYSE:ZTS – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Monday after Piper Sandler lowered their price target on the stock from $90.00 to $80.00. Piper Sandler currently has a neutral rating on the stock. Zoetis traded as low as $71.45 and last traded at $71.8680, with a volume of 1784145 shares traded. The stock had previously closed at $72.66.
Several other equities analysts have also recently weighed in on the stock. William Blair reiterated a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. UBS Group cut their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Citigroup decreased their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, TD Cowen dropped their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and a consensus price target of $110.92.
View Our Latest Research Report on Zoetis
Insider Activity at Zoetis In other news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.22% of the company’s stock.
Key Zoetis News Here are the key news stories impacting Zoetis this week:
Positive Sentiment: Zoetis exceeded second-quarter earnings expectations, reporting adjusted EPS of $1.87 versus the $1.85 consensus estimate. Its full-year 2026 EPS guidance of $6.15–$6.25 also provides an earnings framework for investors. Zoetis Earnings Call Reveals Growth Amid Headwinds Positive Sentiment: JPMorgan lowered its Zoetis price target to $115, but the target remains substantially above the stock’s recent trading level, suggesting the firm still sees potential upside. JPMorgan Chase Cuts Zoetis Price Target Neutral Sentiment: Piper Sandler cut its target from $90 to $80 and moved to a neutral rating. Although the revised target implies approximately 7% upside, the downgrade signals reduced conviction in Zoetis’s near-term performance. Piper Sandler Lowers Zoetis Price Target Neutral Sentiment: Market commentary is focused on whether Wall Street remains bullish or bearish, with the debate centered on Zoetis’s valuation, growth outlook and ability to overcome industry headwinds. Zoetis Stock: Is Wall Street Bullish or Bearish? Negative Sentiment: Second-quarter revenue of $2.47 billion fell short of the $2.50 billion consensus and declined slightly year over year. Coverage also highlights competitive pressures and cautious guidance, weighing on expectations for renewed growth. ZTS Q2 Deep Dive Negative Sentiment: Zoetis is undergoing a finance leadership transition, with the incoming CFO also taking on COO responsibilities. Investors may view the expanded role as a sign of an effort to improve execution during a challenging period. Boards Expand CFO Mandates Negative Sentiment: Recent analyses ask what went wrong after Zoetis was previously viewed as a high-quality growth company, while an investment-manager letter noted underperformance relative to its benchmark. This reinforces concerns about slowing momentum and investor confidence. Zoetis Looked Like a Winner: What Went Wrong? Institutional Inflows and Outflows Several hedge funds have recently bought and sold shares of ZTS. J. Stern & Co. LLP boosted its stake in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. Norges Bank purchased a new stake in shares of Zoetis during the fourth quarter worth about $734,425,000. Vanguard Group Inc. raised its stake in Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Flossbach Von Storch SE bought a new stake in Zoetis during the 2nd quarter valued at approximately $302,601,000. Finally, BlackRock Inc. lifted its holdings in Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Zoetis Trading Up 2.7% The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company has a market capitalization of $31.28 billion, a PE ratio of 12.29, a PEG ratio of 1.21 and a beta of 0.73. The stock has a fifty day moving average of $76.60 and a 200 day moving average of $100.24.
Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the previous year, the company earned $1.76 EPS. The business’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.43 earnings per share for the current fiscal year.
Zoetis Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 34.93%.
About Zoetis (Get Free Report)
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles Five stocks we like better than Zoetis SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat 3 Dividend Champion Utilities for a Market That Can’t Sit Still These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI First Solar’s Profit Engine Faces a New Policy Test in Washington Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEWestwater Resources Sees Unusually High Options Volume (NASDAQ:WWR)
NEXT HEADLINE »Dai Nippon Printing (OTCMKTS:DNPLY) Shares Gap Up on Better-Than-Expected Earnings
Which Pet Stock Should Get Your Tail Wagging in 2024?Zoetis NYSE: ZTS reported second-quarter revenue of $2.5 billion, flat on a reported basis and down 1% organically, as pressure in U.S. companion-animal categories offset growth in livestock, diagnostics and international markets. Adjusted net income was $781 million, down 2% organically, while adjusted diluted earnings per share rose 4% to $1.87, benefiting from a lower share count following share repurchases.
Chief Executive Officer Kristin Peck said the quarter fell short of the company’s expectations amid declining veterinary clinic visits, more selective spending by pet owners and greater promotional activity from competitors. Zoetis lowered its full-year outlook, now expecting organic operational revenue to decline 3% to 1% and adjusted net income to decline 9% to 5%.
Get Zoetis alerts:
Companion-Animal Demand and Competition Weigh on Results MarketBeat Week in Review – 07/31 - 08/04Peck said veterinary clinic visits continued a multiyear decline, while price increases in pet care have outpaced broader consumer inflation. Pet owners have become more selective in their spending, with clinic revenue shifting toward urgent and emergency care and premium preventative and chronic-care products facing pressure, she said.
Global companion-animal revenue was $1.7 billion, down 6% in the quarter. U.S. companion-animal revenue declined 11% to $1 billion, while international companion-animal revenue increased 5% to $664 million.
Rising Dividend Make Zoetis a Doggone WinnerKey dermatology revenue fell 16% to $395 million globally. In the U.S., dermatology revenue declined 18% to $251 million, as canine pruritic clinic visits fell by more than 2%, according to Peck. Chief Financial Officer Wetteny Joseph said the company’s U.S. dermatology franchise retained about 86% in-clinic share during the quarter, though share declined 5 percentage points sequentially and 10 points from a year earlier.
Zoetis has begun using targeted promotions, rebates and other “growth-to-net” investments to protect volume and share rather than lowering list prices, Peck said. Those actions can include clinic-specific promotions, cross-portfolio bundles and point-of-sale discounts for pet owners.
“We are not changing the list price of our products,” Peck said in response to analyst questions. “What we’re talking about is investments in what, in the industry, they’ll call growth to net.”
The Simparica franchise generated $442 million in revenue, flat globally. Simparica Trio revenue fell 1% to $350 million, while Simparica revenue rose 4% to $91 million. International franchise growth was offset by U.S. pressure from softer flea, tick and heartworm visits, as well as a more competitive and promotional marketplace.
U.S. Simparica franchise revenue declined 6% to $308 million. Joseph said Simparica Trio held approximately 21% in-clinic share in U.S. oral parasiticides, nearly double its nearest competitor, and its puppy share was about 28%.
OA Pain Products Show Mixed Performance Global osteoarthritis pain monoclonal-antibody revenue was $147 million, down 3%. Canine OA pain products Librela and Lenivia produced $105 million in revenue, down 8%, while feline OA pain products Solensia and Portela generated $42 million, up 12%.
U.S. canine OA pain revenue declined 24% to $34 million, reflecting a strong prior-year comparison, softer clinic traffic and affordability pressures on premium therapies. International OA pain revenue increased 7% to $96 million, supported by early launches of long-acting Lenivia and Portela in the European Union and Canada.
Peck said Zoetis expects U.S. approval of long-acting Cytopoint later in 2026. The company also said early experience with Lenivia and Portela has been encouraging and that it expects further market expansion in the coming year.
Diagnostics and Livestock Provide Offsets Companion-animal diagnostics revenue rose 12% to $118 million, driven by adoption of technologies including Vetscan Imagyst and Vetscan OptiCell. During the quarter, Zoetis completed its acquisition of VitalRADS, a veterinary teleradiology services platform, expanding its capabilities in veterinary imaging interpretation.
Peck said commercial validation of Vetscan OmniMax, a multimodal chemistry platform that the company views as a potential blockbuster opportunity, remains expected by year-end.
Livestock revenue increased 11% to $731 million, with U.S. livestock revenue rising 23% to $222 million. Growth was driven by cattle and poultry, improved product supply and elevated U.S. demand for Dectomax and other injectable parasiticides in connection with the New World screwworm outbreak.
Joseph said several factors behind the U.S. livestock performance were transitory, including supply timing and screwworm-related demand. Zoetis expects U.S. livestock growth to moderate to the mid-single-digit range in the second half, while citing mid- to high-single-digit growth as a sustainable range for the business’ broader fundamentals.
Guidance Reduced as July Trends Show No Stabilization Zoetis now expects 2026 revenue of $9.12 billion to $9.32 billion. It projected adjusted net income of $2.57 billion to $2.62 billion, adjusted diluted EPS of $6.15 to $6.25, and reported diluted EPS of $5.55 to $5.65.
Joseph said the revised forecast incorporates sales trends through July, which had “not yet indicated market stabilization.” The upper end assumes competitive and pricing pressures remain contained, while the lower end contemplates accelerated pressure, greater dermatology and parasiticide share losses, continued July-like weakness and slower livestock uptake.
The company also cited an additional foreign-exchange headwind of roughly $60 million to $65 million to revenue and about $30 million to profit compared with its prior outlook.
Zoetis repurchased more than $550 million of shares during the quarter. Joseph said the company is maintaining investment in R&D and selected commercial priorities while pursuing cost and productivity actions; adjusted SG&A declined 4% operationally in the quarter.
Separately, Peck said Abhay Nayak was promoted to executive vice president and president of U.S. Commercial Operations. Jay Saccaro will join Zoetis on Aug. 17 as executive vice president, chief financial officer and chief operating officer, a newly created role overseeing finance as well as global manufacturing and supply. Joseph will remain a special advisor on financial matters until early 2027 to support the transition.
About Zoetis (NYSE:ZTS)Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Zoetis Right Now?Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Key Takeaways Zoetis' global Companion Animal revenues fell 6% organically, while U.S. Companion Animal declined 11%.ZTS cut 2026 revenue guidance to $9.12B-$9.32B as July trends showed no market stabilization.Zoetis is using targeted rebates, promotions and bundles to defend volume and share without broad price cuts. Zoetis Inc. (ZTS - Free Report) used its second-quarter 2026 earnings call to reset expectations for 2026 as weaker veterinary clinic traffic, pet-owner price sensitivity and heavier competition pressured major Companion Animal franchises.
CEO Kristin Peck said management is not assuming the market becomes easier soon. The response centers on targeted promotions, sharper commercial execution, cost discipline and continued investment in innovation.
ZTS Faces Tougher Companion Animal ConditionsCEO Kristin Peck said pressure intensified in the second quarter, particularly in Dermatology and U.S. parasiticides. Global Companion Animal revenues fell 6% on an organic operational basis, while U.S. Companion Animal declined 11%.
CFO Wetteny Joseph said Key Dermatology revenues fell 16%, with Apoquel facing softer demand and stronger promotional competition. The Simparica franchise was flat globally as international growth offset U.S. weakness.
ZTS’ second-quarter 2026 adjusted earnings of $1.87 per share exceeded the Zacks Consensus Estimate of $1.84. However, revenues of $2.47 billion missed the Zacks Consensus Estimate of $2.49 billion by 0.90%.
Zoetis Cuts Its 2026 OutlookCFO Wetteny Joseph revised full-year revenue guidance to $9.12 billion to $9.32 billion, implying an organic operational decline of 3% to 1%. Adjusted diluted earnings are now expected at $6.15 to $6.25.
Adjusted net income is projected at $2.57 billion to $2.62 billion, down 9% to 5% organically. CFO Wetteny Joseph said management incorporated July trends, which had not shown market stabilization.
CFO Wetteny Joseph said the high end assumes contained pricing and competitive pressure, manageable share losses in Dermatology and parasiticides, and continued strength in Livestock and Diagnostics. The low end assumes worsening competition, continued July weakness and slower Livestock uptake.
ZTS Uses Promotions to Defend ShareA Morgan Stanley analyst pressed management on pricing. CEO Kristin Peck said Zoetis is avoiding broad list-price cuts and instead using targeted gross-to-net investments, including rebates, promotions, cross-portfolio bundles and point-of-sale support.
A William Blair analyst asked about the margin implications. CEO Kristin Peck reiterated that these actions are intended to protect volume and share while preserving the longer-term value of the franchises.
CFO Wetteny Joseph later told a Stifel analyst that full-year price realization could range from flat to negative 1%, and potentially negative 2% near the low end of guidance, depending on competitive responses.
Zoetis Leans on Livestock and DiagnosticsCEO Kristin Peck highlighted diversification as an important counterweight. Livestock revenue grew 11% organically, while Companion Animal Diagnostics increased 12%.
CFO Wetteny Joseph said U.S. Livestock rose 23%, helped by cattle demand, supply timing and New World screwworm-related demand. He said some Q2 drivers were transitory and expects second-half U.S. Livestock growth to moderate.
CEO Kristin Peck also pointed to Diagnostics as a growth platform. Zoetis completed the VitalRADS acquisition and continued developing Vetscan OmniMax, with commercial validation still expected by year-end.
ZTS Keeps Innovation and Costs in FocusCEO Kristin Peck said Zoetis continues to advance a pipeline containing more than 12 potential blockbusters, including opportunities in chronic kidney disease, oncology, cardiology, anxiety and obesity.
The company is also expanding its OA pain portfolio with Lenivia and Portela in Canada and Europe. CEO Kristin Peck said early experience supported broader launches and reinforced management’s confidence in the category.
CFO Wetteny Joseph said adjusted SG&A declined 4% operationally as cost actions took hold, while adjusted R&D rose 4%. Zoetis also repurchased more than $550 million of shares during the quarter.
Zoetis Reshapes Leadership for ExecutionCEO Kristin Peck framed leadership changes as part of the push for faster execution. Abhay Nayak was promoted to lead U.S. Commercial Operations, where performance has been under pressure.
Jay Saccaro is joining as executive vice president, CFO and COO, combining finance with oversight of global manufacturing and supply. CEO Kristin Peck said the new structure is intended to improve decision-making and connectivity across operations.
Management’s tone remained cautious on the near-term market but firm on its priorities: defend share, control costs, support innovation and use portfolio diversification to navigate weaker Companion Animal demand.
ZTS Zacks Signals Show Conflicting FactorsZTS carries a Zacks Rank #4 (Sell) at present. Its Value Score of A, Momentum Score of A and VGM Score of B are favorable Style Scores, while the Growth Score of D is weaker.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Under the Zacks framework, favorable Style Scores are designed to complement top Zacks Rank #1 or 2 (Buy) stocks, while a Zacks Rank #4 indicates an unfavorable estimate-revision backdrop. The Zacks Rank can change as analysts revise estimates following the latest results.
Saccaro’s Appointment is Effective August 17, 2026; Wetteny Joseph to Serve as a Special Advisor to the CEO on Financial Matters Until Early 2027
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In this newly created role, Mr. Saccaro will lead Zoetis’ global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. With Mr. Saccaro’s appointment, Wetteny Joseph will transition to an advisory role effective August 17, 2026. Mr. Joseph has agreed to remain with the company as a Special Advisor to the CEO on financial matters until early 2027 to facilitate a smooth transition.
Mr. Saccaro joins Zoetis with extensive executive leadership experience at large-scale life sciences companies. He most recently served as Vice President and CFO at GE HealthCare, where he led key initiatives for the newly established public company, including designing processes and approaches across finance, accounting, new product planning, R&D prioritization, and capital allocation, and overseeing the Information Technology function. Previously, Mr. Saccaro spent over two decades at Baxter International Inc., where he held positions of increasing responsibility, culminating in his role as Executive Vice President and CFO for eight years. In that role, he oversaw all aspects of the company’s finance and information technology functions and led a number of high-impact enterprise initiatives, including a margin and cash flow improvement plan following the company's successful spin-off of Baxalta. Mr. Saccaro led business development for Baxter’s $5 billion Medication Delivery unit and played a key role in major M&A.
“We are excited to welcome Jay to Zoetis as we prepare for our next wave of innovation-driven growth,” said Kristin Peck, Chief Executive Officer of Zoetis. “Jay brings a unique combination of skills to this newly created leadership position. He is a seasoned finance executive with 12 years of CFO experience at some of the world's leading healthcare companies and has proven expertise in successfully developing and executing company-wide strategic initiatives. Jay’s track record of designing financial frameworks that balance R&D investment with operational rigor and efficiency will be a significant asset as we sharpen our competitive edge and invest in our future growth platforms. In this expanded role, Jay will also continue to strengthen our global manufacturing and supply operations, enhancing supply chain and distribution performance, and driving greater operational excellence and agility. I look forward to partnering with Jay to build on our industry leadership and deliver sustainable growth and long-term value for shareholders.”
“I am thrilled to join the world’s leading animal health company,” said Mr. Saccaro. “From the company’s deep innovation pipeline to its products that have built and defined categories in the industry, Zoetis is an exceptional business grounded in a deep commitment to setting new standards for the future of animal care. There is tremendous runway to build on that legacy, and alongside Kristin, the leadership team and Zoetis’ talented colleagues, I’m eager to help unlock the opportunities ahead and drive sustainable value creation.”
Ms. Peck added, “On behalf of the Board of Directors and the entire Zoetis team, I thank Wetteny for his strong leadership, partnership, and many important contributions since joining the company five years ago. During his time with Zoetis, Wetteny has helped guide the company through a period of significant investment, change, and growth. We are grateful for his support through this transition and wish him all the best in his next chapter.”
“I am honored to have served as CFO of Zoetis and proud of our team’s accomplishments during my time with the company,” said Mr. Joseph. “I remain confident in Zoetis’ strategy, people and long-term opportunities. Zoetis remains strongly positioned to continue innovating and leading the animal health industry, and I look forward to watching its success for years to come.”
About Jay Saccaro
James (Jay) Saccaro is an accomplished executive with extensive leadership experience across global healthcare and life sciences organizations. He joins Zoetis from GE HealthCare, where he served as Vice President and Chief Financial Officer since 2023, leading the company’s finance, information technology, strategy and business development functions. Prior to GE HealthCare, Mr. Saccaro served as Executive Vice President and CFO at Baxter International Inc. from 2015 to 2023, where he played a key role in leading the company’s post-spin transformation, margin improvement initiatives and capital structure optimization. Prior to rejoining Baxter, Mr. Saccaro was Senior Vice President and CFO at Hill-Rom Corporation. He had previously served as the Corporate Vice President and Treasurer of Baxter from 2011 to 2013. Mr. Saccaro originally joined Baxter in 2002 as manager of strategy for the BioScience business, and over the years assumed positions of increasing responsibility, including vice president of financial planning and vice president of finance for the company’s operations in Europe, Middle East and Africa. He began his career in strategic planning at The Walt Disney Company.
Mr. Saccaro received a bachelor’s degree in economics and master’s degree in engineering-economic systems from Stanford University.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Zoetis Inc. (NYSE:ZTS) reported second-quarter adjusted earnings of $1.87 per share, beating the consensus of $1.86.
The animal health company reported sales of $2.468 billion, missing the consensus of $2.502 billion. Revenue was flat year over year, decreasing 1% on an organic operational basis.
Zoetis Sees Softer Companion Animal Demand And Rising Competition"Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories," said Kristin Peck, CEO of Zoetis.
Read Next
"We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development to strengthen our position in areas aligned with the future of animal health," Peck commented.
The company, in its earnings call, said it faces competitive pressures, particularly in the dermatology and parasiticides sectors, with new entrants using aggressive pricing strategies.
The company also said it is moving with urgency as we navigate the current environment.
U.S. Companion Animal Sales Decline While Livestock Business StrengthensRevenue in the U.S. segment reached $1.3 billion, decreasing 7%. Companion animal product sales decreased 11% due to continued softer end-market demand.
The company’s key dermatology franchise and Simparica Trio faced persistent macro-driven price sensitivity and heightened competitive pressure.
Generic competition also impacted Cerenia and Convenia brands, as well as lower sales of Librela.
U.S. livestock product sales increased 23%, supported by strength across cattle and poultry.
Cattle performance was underpinned by favorable producer economics in beef cattle and supply timing. Poultry performance benefited from increased vaccine sales tied to disease outbreak activity.
Cuts 2026 Guidance As Market Headwinds PersistZoetis updated its 2026 outlook to reflect the headwinds expected to continue in the near term.
The company lowered fiscal 2026 adjusted earnings guidance from $6.85-$7.00 per share to $6.15-$6.25, compared with consensus of $6.88.
Zoetis also cut its 2026 sales guidance from $9.680 billion-$9.96 billion to $9.12 billion-$9.32 billion, compared to the consensus of $9.726 billion.
Management TransitionOn Thursday, Zoetis appointed James (Jay) Saccaro as Executive Vice President, CFO and COO, effective August 17.
With Saccaro’s appointment, Wetteny Joseph will transition to an advisory role.
ZTS Price Action: Zoetis shares were up 3.84% at $77.25 at the time of publication on Thursday, according to Benzinga Pro data.
Read Next
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Key Takeaways ZTS Q2 EPS beat estimates. Revenues were flat year over year and slightly missed expectations.ZTS now expects 2026 revenues of $9.12B-$9.32B and adjusted EPS of $6.15-$6.25, both down from prior outlook.Zoetis faced weaker U.S. companion animal sales, while international and U.S. livestock sales grew. Zoetis, Inc. (ZTS - Free Report) delivered second-quarter 2026 adjusted earnings (excluding one-time items) of $1.87 per share, which beat the Zacks Consensus Estimate of $1.84. In the year-ago quarter, the company had delivered adjusted earnings of $1.76 per share.
Total revenues were flat year over year at $2.47 billion in the second quarter and marginally missed the Zacks Consensus Estimate of $2.49 billion.
Year to date, shares of Zoetis have plunged 40% compared with the industry’s decline of 3.7%.
Image Source: Zacks Investment Research
ZTS’ Q2 Results in DetailZoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
Revenues from the U.S. segment decreased 7% year over year to $1.30 billion in the reported quarter, missing the Zacks Consensus Estimate of $1.33 billion.
Sales of companion animal products in the U.S. region declined 11% year over year to $1.04 billion, owing to softer end-market demand and an increasingly competitive landscape. Zoetis’ key dermatology franchise and Simparica Trio faced heightened competitive pressure and persistent macroeconomic-driven price sensitivity. Also, generic competition for the Convenia and Cerenia brands, as well as lower sales of ZTS’ monoclonal antibody product for osteoarthritis (OA) pain, Librela, for dogs, resulted in the decline.
Sales of livestock products in the United States increased 23% in the quarter to $222 million. The increase was mainly due to broad-based strength across cattle and poultry products.
Revenues in the International segment increased 8% year over year on a reported basis and 6% on an operational basis to $1.17 billion, beating the Zacks Consensus Estimate of $1.14 billion.
Ex-U.S. sales of companion animal products rose 8% on a reported basis and 5% operationally to $664 million, driven by growth in the parasiticides portfolio, including Simparica Trio, along with contributions from Revolution and Stronghold. Growth was also supported by companion animal diagnostics and the OA pain portfolio, following the launches of Lenivia and Portela.
Livestock product sales increased 8% year over year on a reported basis and 6% operationally to $509 million, driven by growth in cattle and poultry.
ZTS’ 2026 GuidanceZoetis lowered its revenue and earnings outlook for 2026.
The company now expects revenues to be in the range of $9.12 billion and $9.32 billion, reflecting an expected operational growth of negative 1-3%.
Previously, the company projected revenues between $9.68 billion and $9.96 billion, representing an expected operational growth of 2-5%.
Adjusted earnings are now expected in the range of $6.15-$6.25 per share in 2026, compared with the previous expectation of $6.85-$7.00 per share.
ZTS’ Zacks Rank and Stocks to ConsiderZoetis currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 3.4% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 158.4% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
Zoetis Inc. (ZTS) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDT
Company Participants
Steven Frank - Vice President of Investor Relations
Kristin Peck - CEO & Director
Wetteny Joseph - Executive VP & CFO
Conference Call Participants
Erin Wilson Wright - Morgan Stanley, Research Division
Brandon Vazquez - William Blair & Company L.L.C., Research Division
Michael Ryskin - BofA Securities, Research Division
David Westenberg - Piper Sandler & Co., Research Division
Christopher Schott - JPMorgan Chase & Co, Research Division
Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division
Daniel Grosslight - Citigroup Inc., Research Division
Presentation
Operator
Welcome to the Second Quarter 2026 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis. The presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com.
The presentation slides can be managed by you, the viewer, and will not be forwarded automatically. In addition, a replay of this call will be available approximately 2 hours after the conclusion of this call via dial-in or on the Investor Relations section of zoetis.com. [Operator Instructions] The floor will be open for you questions following the presentation. [Operator Instructions]
It is now my pleasure to turn the call over to Steve Frank. Steve, you may begin.
Steven Frank
Vice President of Investor Relations
Thank you, operator. Good morning, everyone, and welcome to the Zoetis Second Quarter 2026 Earnings Call. I am joined today by Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Chief Financial Officer. This morning, we issued a press release announcing our financial results.
Before we begin, I would like to remind you that the release and corresponding earnings presentation, which we will reference during this call, are available on the Investor Relations section of our website and that many
Zoetis (ZTS - Free Report) came out with quarterly earnings of $1.87 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $1.76 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +1.63%. A quarter ago, it was expected that this animal health company would post earnings of $1.61 per share when it actually produced earnings of $1.53, delivering a surprise of -4.97%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Zoetis, which belongs to the Zacks Medical - Drugs industry, posted revenues of $2.47 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.95%. This compares to year-ago revenues of $2.46 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Zoetis shares have lost about 40.9% since the beginning of the year versus the S&P 500's gain of 12.8%.
What's Next for Zoetis?While Zoetis has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Zoetis was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.86 on $2.51 billion in revenues for the coming quarter and $6.89 on $9.72 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Vivos Therapeutics, Inc. (VVOS - Free Report) , has yet to report results for the quarter ended June 2026.
This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of +23.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Vivos Therapeutics, Inc.'s revenues are expected to be $5.43 million, up 42.2% from the year-ago quarter.
Zoetis (ZTS - Free Report) reported $2.47 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 0.3%. EPS of $1.87 for the same period compares to $1.76 a year ago.
The reported revenue represents a surprise of -0.95% over the Zacks Consensus Estimate of $2.49 billion. With the consensus EPS estimate being $1.84, the EPS surprise was +1.63%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Zoetis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenues- U.S.: $1.27 billion versus $1.33 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -6.6% change.Geographic Revenues- International Revenue: $1.17 billion versus $1.14 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change.Geographic Revenues- International- Livestock: $509 million versus $491.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.1% change.Geographic Revenues- U.S.- Livestock: $222 million compared to the $191.1 million average estimate based on three analysts. The reported number represents a change of +23.3% year over year.Geographic Revenues- International- Companion Animal: $664 million versus $651.08 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.5% change.Geographic Revenues- U.S.- Companion Animal: $1.04 billion compared to the $1.14 billion average estimate based on three analysts. The reported number represents a change of -11.2% year over year.Revenues- Livestock: $731 million versus $678.9 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.6% change.Revenues- Contract Manufacturing & Human Health: $29 million versus the three-analyst average estimate of $35.13 million. The reported number represents a year-over-year change of -14.7%.Revenues- Companion Animal: $1.71 billion versus the three-analyst average estimate of $1.77 billion. The reported number represents a year-over-year change of -4.5%.View all Key Company Metrics for Zoetis here>>>
Shares of Zoetis have returned -1% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026.
The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational1 basis. Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% and growing 1%, respectively, on a reported basis.
Adjusted net income2 for the second quarter of 2026 was $781 million, or $1.87 per diluted share, decreasing 1% and increasing 5%, respectively, on a reported basis, decreasing 2% and increasing 4%, respectively, on an organic operational basis. Adjusted net income for the second quarter of 2026 excludes the net impact of $90 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
"Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories," said Kristin Peck, Chief Executive Officer of Zoetis. "At the same time, these dynamics reinforce the enduring attractiveness of the markets Zoetis has helped define and advance. We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development to strengthen our position in areas aligned with the future of animal health. We also continue to benefit from the breadth of our diversified portfolio, including strength in Livestock and Diagnostics. As we advance our robust pipeline, including more than 12 potential blockbusters over the coming years, we are acting with urgency and remain confident in the long-term fundamentals of animal health and in Zoetis' ability to compete, lead, and create shareholder value."
SEGMENT HIGHLIGHTS
Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the second quarter of 2026:
Revenue in the U.S. segment totaled $1.3 billion, decreasing 7% on both a reported and an organic operational basis relative to the second quarter of 2025. Companion animal product sales decreased 11% due to continued softer end-market demand. The company's key dermatology franchise and Simparica Trio® faced persistent macro-driven price sensitivity and heightened competitive pressure. Also contributing to the decline was the impact of generic competition on the Cerenia® and Convenia® brands, as well as lower sales of Librela®. Sales of livestock products increased 23% on both a reported and organic operational basis in the quarter, supported by strength across cattle and poultry. Cattle performance was underpinned by favorable producer economics in beef cattle and supply timing. Poultry performance benefited from increased vaccine sales tied to disease outbreak activity. Revenue in the International segment was $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis compared with the second quarter of 2025. Companion animal product sales grew 8% on a reported basis and 5% on an organic operational basis, led by the company's parasiticides portfolio, including Simparica Trio, along with contributions from Revolution® and Stronghold®. Also contributing to growth was companion animal diagnostics, as well as osteoarthritis (OA) pain with the launch of Lenivia® and Portela™, the company's long-acting monoclonal antibody pain products that provide dogs and cats with up to three months of pain relief. These gains were partially offset by lower sales of key dermatology products as well as challenging market conditions impacting the broader portfolio. Sales of livestock products grew 8% on a reported basis and 6% on an organic operational basis, driven by growth in cattle and poultry. INVESTMENTS IN GROWTH
Zoetis continued to advance innovation across its diversified portfolio, including a pipeline with more than 12 potential blockbuster3 candidates in areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity. During the quarter, the company advanced major-market approvals, expanded access to industry-leading treatments in new geographies, enhanced diagnostics capabilities, and delivered solutions to support customers facing emerging and transboundary infectious disease threats. Together, these efforts reflect Zoetis' focus on translating science, global scale and customer insights into solutions that improve the health of companion animals and livestock around the world.
Delivering on Commitment to Innovation
Zoetis is executing on its commitment to deliver a significant approval in a major market every year for the next several years. In July, the company received marketing authorization from the European Commission for Poulvac® Procerta® HVT-ND. This approval reinforces Zoetis’ focus on ensuring a stable and reliable protein supply, helping protect poultry production against Newcastle and Marek’s disease.
Lenivia and Portela, long-acting monoclonal antibody therapies providing dogs and cats with up to three months of OA pain relief from a single injection, launched in Canada and the EU and were approved in Great Britain. Lenivia was also approved in Switzerland.
Supporting Prevention and Treatment of New World Screwworm
With New World screwworm now confirmed in the United States, Zoetis has been well prepared to support customers’ prevention and treatment strategies. Dectomax®-CA1, the first parasite control product to receive FDA conditional approval for the prevention and treatment of New World screwworm myiasis in beef cattle, together with Dectomax®, received emergency use authorization in the U.S. for prevention of infestations in swine, sheep, deer, horses, lactating and dry dairy cows, and dairy replacement heifers. This response underscores Zoetis’ long-standing support for a One Health approach and its ability to deliver targeted solutions when disease threats affect animals, customers, and the broader food supply.
Additional approvals from the quarter include:
Vanguard® crLyme received a label update in the U.S. for effectiveness against subclinical arthritis caused by Borrelia burgdorferi, representing a significant pipeline acceleration. Bonqat®, an oral medication to help alleviate acute anxiety and fear associated with transportation and veterinary visits in cats, was approved in China. Synovex® One Grower gained an expanded label approval in the U.S. to increase the rate of weight gain in growing beef steers and heifers in dry lots or on pasture with insufficient forage. Suvaxyn® PRRS Needle-Free Microdose, a vaccine that helps prevent porcine reproductive and respiratory syndrome, was approved in the EU. This approval includes a needle free intramuscular administration claim and a new multidose presentation. Fostera® Gold PVC MH Flex, a vaccine to help prevent infection from Mycoplasma hyopneumoniae and Porcine circovirus, was approved in Japan. Accelerating Diagnostics Capabilities
In July, Zoetis completed the acquisition of VitalRADS, a veterinary teleradiology services platform. This milestone advances Zoetis’ strategic pursuit of opportunities that unlock new sources of growth by expanding its Global Diagnostics offering with around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform. The acquisition will extend Zoetis’ capabilities beyond in-vitro testing into veterinary imaging interpretation and advance its vision of a more complete end-to-end Virtual Reference Lab.
Zoetis also expanded the capabilities of Vetscan Opticell™, making it the first and only point of care hematology analyzer to offer cellular hemoglobin mean – previously available only in reference laboratories. This expansion adds greater diagnostic depth in clinics and delivers value to veterinary teams through time, cost, and space savings.
Together, these investments strengthen Zoetis’ diagnostics capabilities and reinforce the company’s differentiated position in animal health with scale across both diagnostics and therapeutics.
Advancing Sustainability in Animal Health for a Better Future
In June, Zoetis published its 2025 Sustainability Report, marking the completion of its initial Driven to Care aspirations set in 2021 and introducing the strategy’s next phase, with an even sharper focus across Communities, Animals and the Planet. The report also highlighted that the Zoetis Foundation fulfilled its commitment to distribute $35 million in grants from 2021 to 2025, helping strengthen the animal health ecosystem by advancing opportunities for veterinary professionals and livestock farmers.
FINANCIAL GUIDANCE
Zoetis is providing updated guidance based on the current operating environment.
Revenue of $9.120 billion to $9.320 billion (organic operational growth of (3)% to (1)%) Reported net income of $2.330 billion to $2.380 billion Adjusted net income of $2.570 billion to $2.620 billion (organic operational growth of (9)% to (5)%) Reported diluted EPS of $5.55 to $5.65 Adjusted diluted EPS of $6.15 to $6.25 This guidance reflects foreign exchange rates as of July 21, 2026. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call.
WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call today at 8:30 a.m. ET to review second quarter 2026 results, discuss financial guidance and respond to questions from financial analysts. The live webcast and corresponding slides can be accessed by visiting https://investor.zoetis.com/events-presentations. A replay of the webcast will be available following the event.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
1 Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.
2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
3 A blockbuster has annual sales of at least $100 million.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; possible impacts of the Fiscal Year Alignment; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share, operational results (which exclude the impact of foreign exchange) and organic operational results (which exclude the impact of foreign exchange and certain acquisitions and divestitures), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.
Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.
ZTS-COR
ZTS-IR
ZTS-FIN
ZOETIS INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
(millions of dollars, except per share data)
Three Months Ended
Six Months Ended
June 30,
June 30,
2026
2025
% Change
2026
2025
% Change
Revenue
$
2,468
$
2,474
—
$
4,730
$
4,672
1
Costs and expenses:
Cost of sales
673
664
1
1,314
1,282
2
Selling, general and administrative expenses
592
614
(4
)
1,180
1,188
(1
)
Research and development expenses
173
166
4
353
328
8
Amortization of intangible assets
31
33
(6
)
62
65
(5
)
Restructuring charges and certain acquisition and divestiture-related costs
77
30
*
99
30
*
Interest expense, net of capitalized interest
61
53
15
123
107
15
Other (income)/deductions–net
(5
)
2
*
(25
)
(13
)
92
Income before provision for taxes on income
866
912
(5
)
1,624
1,685
(4
)
Provision for taxes on income
175
186
(6
)
332
357
(7
)
Net income before allocation to noncontrolling interests
691
726
(5
)
1,292
1,328
(3
)
Less: Net income/(loss) attributable to noncontrolling interests
—
—
*
—
—
*
Net income attributable to Zoetis Inc.
$
691
$
726
(5
)
$
1,292
$
1,328
(3
)
Earnings per share attributable to Zoetis—basic
$
1.65
$
1.63
1
$
3.08
$
2.98
3
Earnings per share attributable to Zoetis—diluted
$
1.65
$
1.63
1
$
3.08
$
2.97
4
Weighted-average shares used to calculate earnings per share
Basic
417.6
445.1
419.9
446.3
Diluted
417.7
445.5
420.1
446.7
* Calculation not meaningful.
ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
Three Months Ended June 30, 2026
GAAP Reported
Purchase Accounting Adjustments
Acquisition and Divestiture- Related Costs(1)
Certain Significant Items(2)
Non-GAAP Adjusted(a)
Cost of sales
$
673
$
(1
)
$
—
$
(3
)
$
669
Gross profit
1,795
1
—
3
1,799
Selling, general and administrative expenses
592
(3
)
—
(3
)
586
Amortization of intangible assets
31
(26
)
—
—
5
Restructuring charges and certain acquisition and divestiture-related costs
77
—
(2
)
(75
)
—
Income before provision for taxes on income
866
30
2
81
979
Provision for taxes on income
175
6
—
17
198
Net income attributable to Zoetis
691
24
2
64
781
Earnings per common share attributable to Zoetis–diluted
1.65
0.06
—
0.16
1.87
Three Months Ended June 30, 2025
GAAP Reported
Purchase Accounting Adjustments
Acquisition and Divestiture- Related Costs(1)
Certain Significant Items(2)
Non-GAAP Adjusted(a)
Cost of sales
$
664
$
(1
)
$
—
$
(2
)
$
661
Gross profit
1,810
1
—
2
1,813
Selling, general and administrative expenses
614
(2
)
—
(9
)
603
Research and development expenses
166
(1
)
—
—
165
Amortization of intangible assets
33
(29
)
—
—
4
Restructuring charges and certain acquisition and divestiture-related costs
30
—
(1
)
(29
)
—
Other (income)/deductions–net
2
—
—
(8
)
(6
)
Income before provision for taxes on income
912
33
1
48
994
Provision for taxes on income
186
8
—
9
203
Net income attributable to Zoetis
726
25
1
39
791
Earnings per common share attributable to Zoetis–diluted
1.63
0.06
—
0.09
1.78
(a) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).
ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
Six Months Ended June 30, 2026
GAAP Reported
Purchase Accounting Adjustments
Acquisition and Divestiture- Related Costs(1)
Certain Significant Items(2)
Non-GAAP Adjusted(a)
Cost of sales
$
1,314
$
(2
)
$
—
$
(5
)
$
1,307
Gross profit
3,416
2
—
5
3,423
Selling, general and administrative expenses
1,180
(2
)
—
(7
)
1,171
Research and development expenses
353
(1
)
—
—
352
Amortization of intangible assets
62
(53
)
—
—
9
Restructuring charges and certain acquisition and divestiture-related costs
99
—
(4
)
(95
)
—
Other (income)/deductions–net
(25
)
—
—
(1
)
(26
)
Income before provision for taxes on income
1,624
58
4
108
1,794
Provision for taxes on income
332
13
1
21
367
Net income attributable to Zoetis
1,292
45
3
87
1,427
Earnings per common share attributable to Zoetis–diluted
3.08
0.11
—
0.21
3.40
Six Months Ended June 30, 2025
GAAP Reported
Purchase Accounting Adjustments
Acquisition and Divestiture- Related Costs(1)
Certain Significant Items(2)
Non-GAAP Adjusted(a)
Cost of sales
$
1,282
$
(2
)
$
—
$
(2
)
$
1,278
Gross profit
3,390
2
—
2
3,394
Selling, general and administrative expenses
1,188
(5
)
—
(15
)
1,168
Research and development expenses
328
(1
)
—
—
327
Amortization of intangible assets
65
(57
)
—
—
8
Restructuring charges and certain acquisition and divestiture-related costs
30
—
(1
)
(29
)
—
Other (income)/deductions–net
(13
)
—
—
(8
)
(21
)
Income before provision for taxes on income
1,685
65
1
54
1,805
Provision for taxes on income
357
15
—
9
381
Net income attributable to Zoetis
1,328
50
1
45
1,424
Earnings per common share attributable to Zoetis–diluted
2.97
0.12
—
0.10
3.19
(a) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).
ZOETIS INC.
NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars)
(1) Acquisition and divestiture-related costs include the following:
Three Months Ended
Six Months Ended
June 30,
June 30,
2026
2025
2026
2025
Acquisition-related costs(a)
$
2
$
1
$
4
$
1
Total acquisition and divestiture-related costs—pre-tax
2
1
4
1
Income taxes(b)
—
—
1
—
Total acquisition and divestiture-related costs—net of tax
$
2
$
1
$
3
$
1
(a) Acquisition-related costs represent external, incremental costs that directly relate to transacting and integrating businesses, included in Restructuring charges and certain acquisition and divestiture-related costs.
(b) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.
(2) Certain significant items include the following:
Three Months Ended
Six Months Ended
June 30,
June 30,
2026
2025
2026
2025
Other restructuring charges and cost-reduction/productivity initiatives(a)
$
75
$
7
$
95
$
7
Business process transformation program(b)
6
11
11
18
Certain asset impairment charges(c)
—
27
—
27
Net loss on sale of business(d)
—
3
—
3
Other
—
—
2
(1
)
Total certain significant items—pre-tax
81
48
108
54
Income taxes(e)
17
9
21
9
Total certain significant items—net of tax
$
64
$
39
$
87
$
45
(a) For the three and six months ended June 30, 2026, primarily driven by employee termination costs under a comprehensive cost and productivity program, with the six-month period also reflecting employee termination costs from additional organizational structure refinements.
For the three and six months ended June 30, 2025, primarily consisted of employee termination costs related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs.
(b) Represents costs related to our multi-year business process transformation program, which includes the implementation of a new enterprise resource planning (ERP) system, related digital technology solutions and other related costs, included in Selling, general and administrative expenses and Cost of sales. This comprehensive program is a major global and cross-functional company-wide effort that we believe will transform how we work across our business and contribute to all of our strategic priorities. Due to the nature, scope and magnitude of this investment, these costs are incremental transformational costs that are far in excess of the historical normal level of spending to support operations and are not expected to recur in the foreseeable future.
(c) Represents certain asset impairment charges related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs, as well as charges related to our aquaculture product portfolio included in Other (income)/deductions–net.
(d) Represents a net loss related to the sale of our medicated feed additive product portfolio, certain water soluble products and related assets sold in 2024, included in Other (income)/deductions–net.
(e) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.
ZOETIS INC.
ADJUSTED SELECTED COSTS, EXPENSES AND INCOME(a)
(UNAUDITED)
(millions of dollars)
Three Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
Divestitures
Organic Operational(c)
Adjusted cost of sales
$
669
$
661
1
%
3
%
(2
)%
as a percent of revenue
27.1
%
26.7
%
NA
NA
NA
Adjusted SG&A expenses
586
603
(3
)%
1
%
(4
)%
Adjusted R&D expenses
173
165
5
%
1
%
4
%
Adjusted net income
781
791
(1
)%
1
%
(2
)%
—
%
(2
)%
Six Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
Divestitures
Organic Operational(c)
Adjusted cost of sales
$
1,307
$
1,278
2
%
6
%
(4
)%
as a percent of revenue
27.6
%
27.4
%
NA
NA
NA
Adjusted SG&A expenses
1,171
1,168
—
%
2
%
(2
)%
Adjusted R&D expenses
352
327
8
%
2
%
6
%
Adjusted net income
1,427
1,424
—
%
1
%
(1
)%
—
%
(1
)%
(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.
2026 GUIDANCE
Selected Line Items
(millions of dollars, except per share amounts)
Full Year 2026
as of August 6, 2026
Full Year 2026
as of May 7, 2026
(Prior Guidance)
Revenue
$9,120 to $9,320
$9,680 to $9,960
Organic operational results(a)
(3)% to (1)%
2% to 5%
Adjusted cost of sales as a percentage of revenue(b)
Approximately 29.0%
Approximately 28.5%
Adjusted SG&A expenses(b)
$2,330 to $2,380
$2,350 to $2,400
Adjusted R&D expenses(b)
$720 to $730
$735 to $745
Adjusted interest expense and other (income)/deductions-net(b)
Approximately $215
Approximately $215
Effective tax rate on adjusted income(b)
Approximately 20.5%
Approximately 20.5%
Adjusted diluted EPS(b)
$6.15 to $6.25
$6.85 to $7.00
Adjusted net income(b)
$2,570 to $2,620
$2,870 to $2,950
Organic operational results(a)(c)
(9)% to (5)%
2% to 6%
Certain significant items and acquisition and divestiture-related costs(d)
Approximately $150
Approximately $100
Reported diluted EPS
$5.55 to $5.65
$6.35 to $6.50
The guidance reflects foreign exchange rates as of July 21, 2026.
Reconciliations of 2026 reported guidance to 2026 adjusted guidance follows:
(millions of dollars, except per share amounts) Reported
Certain significant items and acquisition and divestiture-related costs(d)
Purchase accounting
Adjusted(b)
Cost of sales as a percentage of revenue
~ 29.2%
~ (0.2%)
~ 29.0%
SG&A expenses
$2,350 to $2,400
~ $(12)
~ $(8)
$2,330 to $2,380
R&D expenses
$722 to $732
~ $(2)
$720 to $730
Interest expense and other (income)/deductions-net
~ $215
~ $215
Effective tax rate
~ 20.6%
~ (0.1%)
~ 20.5%
Diluted EPS
$5.55 to $5.65
~ $0.38
~ $0.22
$6.15 to $6.25
Net income attributable to Zoetis
$2,330 to $2,380
~ $150
~ $90
$2,570 to $2,620
(a) Organic operational results (a non-GAAP financial measure) excludes the impact of foreign exchange and certain acquisitions and divestitures.
(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.
(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational results to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition and divestiture-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.
(d) Primarily includes certain nonrecurring costs related to acquisitions, divestitures and other charges.
ZOETIS INC.
CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES
(UNAUDITED)
(millions of dollars)
Three Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
Divestitures
Organic Operational(c)
Revenue:
Companion Animal
$
1,708
$
1,790
(5
)%
1
%
(6
)%
—
%
(6
)%
Livestock
731
651
12
%
2
%
10
%
(1
)%
11
%
Contract Manufacturing & Human Health
29
33
(12
)%
1
%
(13
)%
—
%
(13
)%
Total Revenue
$
2,468
$
2,474
—
%
2
%
(2
)%
(1
)%
(1
)%
U.S.:
Companion Animal
$
1,044
$
1,176
(11
)%
—
%
(11
)%
—
%
(11
)%
Livestock
222
180
23
%
—
%
23
%
—
%
23
%
Total U.S. Revenue
$
1,266
$
1,356
(7
)%
—
%
(7
)%
—
%
(7
)%
International:
Companion Animal
$
664
$
614
8
%
3
%
5
%
—
%
5
%
Livestock
509
471
8
%
4
%
4
%
(2
)%
6
%
Total International Revenue
$
1,173
$
1,085
8
%
3
%
5
%
(1
)%
6
%
Companion Animal:
Dogs and Cats
$
1,634
$
1,719
(5
)%
1
%
(6
)%
Horses
74
71
4
%
1
%
3
%
Total Companion Animal Revenue
$
1,708
$
1,790
(5
)%
1
%
(6
)%
Livestock:
Cattle
$
390
$
323
21
%
3
%
18
%
Swine
117
118
(1
)%
2
%
(3
)%
Poultry
115
104
11
%
1
%
10
%
Fish
83
81
2
%
4
%
(2
)%
Sheep and other
26
25
4
%
8
%
(4
)%
Total Livestock Revenue
$
731
$
651
12
%
2
%
10
%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.
(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.
CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES
(UNAUDITED)
(millions of dollars)
Six Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
Divestitures
Organic Operational(c)
Revenue:
Companion Animal
$
3,227
$
3,331
(3
)%
2
%
(5
)%
—
%
(5
)%
Livestock
1,451
1,278
14
%
4
%
10
%
(1
)%
11
%
Contract Manufacturing & Human Health
52
63
(17
)%
1
%
(18
)%
—
%
(18
)%
Total Revenue
$
4,730
$
4,672
1
%
2
%
(1
)%
—
%
(1
)%
U.S.:
Companion Animal
$
1,909
$
2,149
(11
)%
—
%
(11
)%
—
%
(11
)%
Livestock
447
390
15
%
—
%
15
%
—
%
15
%
Total U.S. Revenue
$
2,356
$
2,539
(7
)%
—
%
(7
)%
—
%
(7
)%
International:
Companion Animal
$
1,318
$
1,182
12
%
6
%
6
%
—
%
6
%
Livestock
1,004
888
13
%
5
%
8
%
(2
)%
10
%
Total International Revenue
$
2,322
$
2,070
12
%
5
%
7
%
(1
)%
8
%
Companion Animal:
Dogs and Cats
$
3,077
$
3,196
(4
)%
2
%
(6
)%
Horses
150
135
11
%
3
%
8
%
Total Companion Animal Revenue
$
3,227
$
3,331
(3
)%
2
%
(5
)%
Livestock:
Cattle
$
782
$
664
18
%
4
%
14
%
Swine
240
223
8
%
4
%
4
%
Poultry
233
210
11
%
2
%
9
%
Fish
149
136
10
%
7
%
3
%
Sheep and other
47
45
4
%
7
%
(3
)%
Total Livestock Revenue
$
1,451
$
1,278
14
%
4
%
10
%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.
(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.
CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS
(UNAUDITED)
(millions of dollars)
Three Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Divestitures
Organic Operational(a)
Total International
$
1,173
$
1,085
8
%
3
%
(1
)%
6
%
Australia
94
83
13
%
11
%
—
%
2
%
Brazil
103
93
11
%
11
%
—
%
—
%
Canada
72
71
1
%
—
%
(5
)%
6
%
Chile
34
34
—
%
—
%
—
%
—
%
China
62
67
(7
)%
7
%
—
%
(14
)%
France
40
42
(5
)%
3
%
—
%
(8
)%
Germany
69
57
21
%
2
%
—
%
19
%
Italy
40
37
8
%
1
%
—
%
7
%
Japan
41
43
(5
)%
(11
)%
—
%
6
%
Mexico
47
39
21
%
15
%
—
%
6
%
Spain
43
40
8
%
2
%
(1
)%
7
%
United Kingdom
72
81
(11
)%
(1
)%
(1
)%
(9
)%
Other developed markets
187
175
7
%
3
%
—
%
4
%
Other emerging markets
269
223
21
%
1
%
(1
)%
21
%
Six Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Divestitures
Organic Operational(a)
Total International
$
2,322
$
2,070
12
%
5
%
(1
)%
8
%
Australia
183
162
13
%
11
%
—
%
2
%
Brazil
193
174
11
%
11
%
—
%
—
%
Canada
145
141
3
%
3
%
(6
)%
6
%
Chile
72
69
4
%
2
%
—
%
2
%
China
125
122
2
%
5
%
—
%
(3
)%
France
77
81
(5
)%
6
%
—
%
(11
)%
Germany
128
112
14
%
6
%
—
%
8
%
Italy
79
67
18
%
8
%
(1
)%
11
%
Japan
76
75
1
%
(8
)%
—
%
9
%
Mexico
95
74
28
%
16
%
—
%
12
%
Spain
83
69
20
%
7
%
(1
)%
14
%
United Kingdom
150
155
(3
)%
3
%
(1
)%
(5
)%
Other developed markets
356
308
16
%
7
%
—
%
9
%
Other emerging markets
560
461
21
%
1
%
(1
)%
21
%
(a) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.
ZOETIS INC.
SEGMENT(a) EARNINGS
(UNAUDITED)
(millions of dollars)
Three Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
U.S.:
Revenue
$
1,266
$
1,356
(7
)%
—
%
(7
)%
Cost of Sales
214
208
3
%
—
%
3
%
Gross Profit
1,052
1,148
(8
)%
—
%
(8
)%
Gross Margin
83.1
%
84.7
%
Operating Expenses
215
218
(1
)%
—
%
(1
)%
Other (income)/deductions-net
—
—
*
*
*
U.S. Earnings
$
837
$
930
(10
)%
—
%
(10
)%
International:
Revenue
$
1,173
$
1,085
8
%
3
%
5
%
Cost of Sales
340
321
6
%
4
%
2
%
Gross Profit
833
764
9
%
3
%
6
%
Gross Margin
71.0
%
70.4
%
Operating Expenses
172
171
1
%
3
%
(2
)%
Other (income)/deductions-net
—
1
*
*
*
International Earnings
$
661
$
592
12
%
4
%
8
%
Total Reportable Segments
$
1,498
$
1,522
(2
)%
1
%
(3
)%
Other business activities(c)
(135
)
(129
)
5
%
Reconciling Items:
Corporate(d)
(315
)
(324
)
(3
)%
Purchase accounting adjustments(e)
(30
)
(33
)
(9
)%
Acquisition and divestiture-related costs(f)
(2
)
(1
)
*
Certain significant items(g)
(81
)
(48
)
69
%
Other unallocated(h)
(69
)
(75
)
(8
)%
Total Earnings(i)
$
866
$
912
(5
)%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i) Defined as income before provision for taxes on income.
* Calculation not meaningful.
ZOETIS INC.
SEGMENT(a) EARNINGS
(UNAUDITED)
(millions of dollars)
Six Months Ended
June 30,
% Change
2026
2025
Reported Change
Foreign Exchange
Operational(b)
U.S.:
Revenue
$
2,356
$
2,539
(7
)%
—
%
(7
)%
Cost of Sales
408
407
—
%
—
%
—
%
Gross Profit
1,948
2,132
(9
)%
—
%
(9
)%
Gross Margin
82.7
%
84.0
%
Operating Expenses
414
423
(2
)%
—
%
(2
)%
Other (income)/deductions-net
—
—
*
*
*
U.S. Earnings
$
1,534
$
1,709
(10
)%
—
%
(10
)%
International:
Revenue
$
2,322
$
2,070
12
%
5
%
7
%
Cost of Sales
674
616
9
%
6
%
3
%
Gross Profit
1,648
1,454
13
%
4
%
9
%
Gross Margin
71.0
%
70.2
%
Operating Expenses
347
334
4
%
5
%
(1
)%
Other (income)/deductions-net
1
1
*
*
*
International Earnings
$
1,300
$
1,119
16
%
5
%
11
%
Total Reportable Segments
$
2,834
$
2,828
—
%
2
%
(2
)%
Other business activities(c)
(276
)
(262
)
5
%
Reconciling Items:
Corporate(d)
(630
)
(602
)
5
%
Purchase accounting adjustments(e)
(58
)
(65
)
(11
)%
Acquisition and divestiture-related costs(f)
(4
)
(1
)
*
Certain significant items(g)
(108
)
(54
)
*
Other unallocated(h)
(134
)
(159
)
(16
)%
Total Earnings(i)
$
1,624
$
1,685
(4
)%
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.
(i) Defined as income before provision for taxes on income.
Animal health company Zoetis cut its annual forecasts on Thursday after missing Wall Street estimates for second-quarter revenue, as softer demand for pet healthcare products and increased competition weighed.
The upcoming report from Zoetis (ZTS - Free Report) is expected to reveal quarterly earnings of $1.84 per share, indicating an increase of 4.6% compared to the year-ago period. Analysts forecast revenues of $2.49 billion, representing an increase of 1.3% year over year.
The current level reflects a downward revision of 0.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Zoetis metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Revenues- Livestock' will reach $678.90 million. The estimate points to a change of +6.4% from the year-ago quarter.
The consensus estimate for 'Revenues- Contract Manufacturing & Human Health' stands at $35.13 million. The estimate suggests a change of +3.3% year over year.
Based on the collective assessment of analysts, 'Revenues- Companion Animal' should arrive at $1.77 billion. The estimate suggests a change of -0.9% year over year.
The average prediction of analysts places 'Geographic Revenues- U.S.' at $1.33 billion. The estimate indicates a change of -2.2% from the prior-year quarter.
Analysts forecast 'Geographic Revenues- U.S.- Livestock' to reach $191.10 million. The estimate suggests a change of +6.2% year over year.
The combined assessment of analysts suggests that 'Geographic Revenues- International- Companion Animal' will likely reach $651.08 million. The estimate indicates a change of +6.4% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenues- International Revenue' reaching $1.14 billion. The estimate indicates a change of +6.8% from the prior-year quarter.
According to the collective judgment of analysts, 'Geographic Revenues- International- Livestock' should come in at $491.12 million. The estimate indicates a change of +7.2% from the prior-year quarter.
The consensus among analysts is that 'Geographic Revenues- U.S.- Companion Animal' will reach $1.14 billion. The estimate indicates a change of -3.5% from the prior-year quarter.
View all Key Company Metrics for Zoetis here>>>
Shares of Zoetis have demonstrated returns of +2.2% over the past month compared to the Zacks S&P 500 composite's +1.7% change. With a Zacks Rank #4 (Sell), ZTS is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Key Takeaways Zoetis is expected to report Q2 revenues of $2.49B and earnings of $1.84 per share on Aug. 6, 2026. ZTS may see weaker U.S. sales amid competition and Librela pressure, offset by international growth.Zoetis could benefit from demand for Apoquel, Cytopoint, Simparica Trio and livestock products. Zoetis, Inc. (ZTS - Free Report) is slated to report second-quarter results on Aug. 6, 2026, before the opening bell.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $2.49 billion. The consensus mark for earnings is pinned at $1.84 per share.
Let's see how things might have shaped up for Zoetis in the soon-to-be-reported quarter.
Factors to Consider Regarding ZTS’ Q2 EarningsZoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
First-quarter revenues in the U.S. segment are likely to have decreased from the year-ago quarter, primarily due to lower sales of Zoetis’ companion animal products and an increasingly competitive landscape. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.33 billion.
Revenues from the International segment are expected to have increased in the to-be-reported quarter due to higher sales of companion animal and livestock products. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.14 billion.
Year to date, Zoetis shares have plunged 38.6% compared with the industry’s 4.5% decline.
Image Source: Zacks Investment Research
Companion animal products sales, particularly ZTS’ parasiticides portfolio, including Simparica and ProHeart franchises, and its key dermatology products, including Apoquel and Cytopoint, are expected to have driven revenues in both the U.S. and International segments in the to-be-reported quarter.
However, Zoetis’ monoclonal antibody products for osteoarthritis pain, Librela for dogs and Solensia for cats, are expected to have posted a decline in sales in the U.S. segment due to fears of side effects in some dogs.
Apoquel is also approved as the first and only chewable treatment in the United States for controlling pruritus related to allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. The drug’s expanded label is likely to have boosted sales in the first quarter.
In 2025, the FDA approved a new indication for Zoetis’ Simparica Trio to prevent flea tapeworm infections by targeting and killing vector fleas in treated dogs. With this approval, the triple combo drug is now the only canine combination parasiticide indicated to prevent flea tapeworm infections at the source by eliminating carrier fleas before they can transmit the parasite. The label expansion is expected to have driven sales in the to-be-reported quarter.
Zoetis' livestock product sales are expected to have increased in the second quarter, supported by continued broad-based strength across its core species portfolio. In the United States, growth is likely to have been driven by cattle, poultry and swine products, while the International segment is expected to have benefited from broad-based demand across cattle, swine, poultry and fish.
ZTS Earnings Surprise HistoryZoetis has a mixed earnings surprise history so far. The bottom line surpassed estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average surprise of 3.58%. In the last reported quarter, the company delivered a negative surprise of 4.97%.
Earnings Whispers for ZTSOur proven model does not predict an earnings beat for Zoetis this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: ZTS has an Earnings ESP of -0.75%.
Zacks Rank: Zoetis currently carries a Zacks Rank #4 (Sell).
Stocks to ConsiderHere are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Harmony Biosciences (HRMY - Free Report) has an Earnings ESP of +14.14% and sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of HRMY have lost 5.9% year to date. The company’s earnings missed estimates in each of the trailing four quarters, delivering an average negative surprise of 25.16%. Harmony is scheduled to report second-quarter results on Aug. 4, before the opening bell.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +25.00% and a Zacks Rank #2 at present.
Shares of ACAD have lost 3.1% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average surprise of 20.83%. Acadia is scheduled to report second-quarter results on Aug. 4.
CRISPR Therapeutics (CRSP - Free Report) has an Earnings ESP of +1.94% and a Zacks Rank #3 at present.
Shares of CRSP have lost 8.4% year to date. CRISPR’s earnings beat estimates in two of the trailing four quarters and missed on the remaining two occasions, delivering an average negative surprise of 1.95%.
Zoetis (ZTS - Free Report) closed at $76.92 in the latest trading session, marking a +2.08% move from the prior day. This move outpaced the S&P 500's daily gain of 0.02%. On the other hand, the Dow registered a gain of 0.51%, and the technology-centric Nasdaq decreased by 0.18%.
The stock of animal health company has fallen by 0.97% in the past month, lagging the Medical sector's gain of 3.09% and the S&P 500's gain of 0.77%.
Investors will be eagerly watching for the performance of Zoetis in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 6, 2026. The company's earnings per share (EPS) are projected to be $1.84, reflecting a 4.55% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $2.49 billion, reflecting a 1.29% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.89 per share and a revenue of $9.72 billion, signifying shifts of +7.49% and +2.66%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Zoetis. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.13% fall in the Zacks Consensus EPS estimate. Right now, Zoetis possesses a Zacks Rank of #4 (Sell).
From a valuation perspective, Zoetis is currently exchanging hands at a Forward P/E ratio of 10.94. This expresses a discount compared to the average Forward P/E of 17.14 of its industry.
It's also important to note that ZTS currently trades at a PEG ratio of 1.17. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Drugs industry held an average PEG ratio of 1.72.
The Medical - Drugs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 94, finds itself in the top 39% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
New York, New York--(Newsfile Corp. - July 27, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/ZTS.
Zoetis Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment while failing to disclose that:
veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; Zoetis' Simparica Trio was losing significant market share to a lower-priced competing canine parasiticide with broader indicated use in a slowing overall market; and Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.What's Next for Zoetis Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/ZTS, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Zoetis you have until July 27, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Zoetis Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Zoetis Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299407
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - July 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis' flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306670
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
